Zum Inhalt springenZur Suche springen

Publikationen

Originalarbeiten

2021

K. Szczepanska, S. Pockes, S. Podlewska, C. Höring, K. Mika, G. Latacz, M. Bednarski, A. Siwek, T. Karcz, M. Nagl, M. Bresinsky, D. Mönnich, U. Seibel, K. J. Kuder, M. Kotanska, H. Stasrk, S. Elz, and K. Kiec-Kononowicz.
Structural Modifications in the Distal, Regulatory Region of Histamine H3 Receptor Antagonists Leading to the Identification of a Potent Anti-obesity Agent.
Eur. J. Med. Chem. in press (doi:10.1016/j.ejmech.2020.113041)

F. Imeri, B. S. Tanturovska, A. Zivkovic, G. Enzmann, S. Schwalm, J Pfeilschifter, T. Homann, B. Kleuser, B. Engelhardt, H. Stark*, and A. Huwiler*.
Novel Compounds with Dual S1P Receptor Agonist and Histamine H3 Receptor Antagonsit Activities Act Protective in a Mouse Model of Multiple Sclerosis.
Neuropharmacology, in press (doi: 10.1016/j.neuropharm/2021.108464)

2020

M. Bajda, D. Lazewska, J. Godyn, P. Zareba, K. Kuder, S. Hagenow, K. Latka, E. Stawarska, H. Stark, K. Kiec-Kononowicz, and B. Malawska.
Search for New Multi-Target Compounds Against Alzheimer´s Disease among Histamine H3 Receptor Ligands.
Eur. J. Med. Chem. 2020, 185, 111785.
Corrigendum – Eur. J. Med. Chem. 2020, 205, 112611.

M. F. Correa, D. Reiner, G. A. B. Fernandes, M. T. Varela, C. M. S, Q. Aranha, H. Stark, and J. P. S. Fernandes.
Profiling of LINS01 Compounds at Human Dopamine D2 and D3 Receptors.
J. Chem. Sci. 2020, 132, 5. Doi.org/10.1007/s12039-019-1694-6.

A. Smelcerovic*, A. Zivkovic, B. S. Ilic, B. Hofmann, D. Steinhilber, and H. Stark*.
4-(4-Chloropenyl)thiazol-2-amines as Pioneers of Potential Neurodegenerative Therapeutics with Anti-inflammatory Properties Based on Dual DNAse I and 5-LO Inhibition.
Bioorg. Chem. 2020, 95, 103529.

M. Schultes, M. Dubiel, und H. Stark.
Tinnitus – Ich höre etwas, das Du nicht hörst.
[Tinnitus – I hear something, that you do not.]
Pharmakon 2020, 8, 15-28.

N. Ghamari, S. Dastmalchi, O. Zarei, J.-A. Arias-Montano, D. Reiner, F. Ustun-Alkan, H. Stark, and M. Hamzeh-Mivehroud.
In Silico and In Vitro Studies of Two Non-imidazole Multiple Targeting Agents at Histamine H3 Receptors and Cholinesterase Enzymes.
Chem. Biol. Drug Des. 2020, 95, 279-290.

J. Hagenow, S. Hagenow, K. Grau, M. Khanfar, L. Hefke, E. Proschak, and H. Stark.
Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs.
Drug Des. Developm. Ther. 2020, 14, 371-393.

D. Reiner, A. Zivkovic, O. Labeeuw, S. Krief, M. Capet, and H. Stark.
Novel Pyrrolidinone Derivative Lacks Claimed Histamine H3 Receptor Stimulation in Receptor Binding and Functional Studies.
Eur. J. Med. Chem. 2020, 191, 112150 doi: 10.1016/j.ejmechem.2020.112159.

E. P. Gonzales*, S. Hagenow, M. A. Murillo, H. Stark*, and L. C. Suarez.
Isoquinoline Alkaloids from the Roots of Zanthoxylum rigidum as Multi-Target Inhibitors of Cholinesterase, Monoamine Oxidase and Ab1-42 Aggregation.
Bioorg. Chem. 2020, 98, 103722. Doi: 10.1016/j.bioorg.2020.103722.

A. Alachkar, S. K. Ohja, A. Sadeq, A. Adem, A. Frank, H. Stark, and B. Sadek.
Experimental Models for Discovery of Novel Anticonvulsant Drugs: Focus on Pentylentetrazole-Induced Seizures and Associated Memory Deficits.
Curr. Pharm. Des. 2020, in press, doi: 10.2174/138161282666620013110532.

D. Lazewska, A. Olejarz-Maciej, D. Reiner, M. Kaleta, G. Latacz, M. Zygmunt, A. Doroz-Plonka, T. Karcz, A. Frank, H. Stark, and K. Kiec-Konowicz.
Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors.
Int. J. Mol. Sci. 2020, 21(10), 3411. (open access) https://doi.org/10.3390/ijms21103411

H. Stark.
The Chemical Probe – Scopes, Limitations and Challenges.
Exp. Opin. Drug Disc. 2020, 19, 1362-1367 (1-3). doi: 10.1080/17460441.2020.1781086.

N. Eissa, S. Azimullah, P. Jayaprakash, R. L. Jayaraj, D. Reiner, S. K. Ojha, R. Beiram, H. Stark, D. Lazewska, K. Kiec-Konowicz, and B. Sadek.
The Dual-Active Histamine H3 Receptor Antagonist and Acetylcholine Esterase Inhibitor E100 Alleviates Autistic-Like Behaviors and Oxidative Stress in Valproic Acid Induced Autism in Mice.
Int. J. Mol. Sci. 2020, 21, 3996. (open access) .

D. Reiner, L. Seifert, C. Decker, M. Jung, and H. Stark.
Epigenetic meets GPCR: Inhibition of Histone H3 Methyltransferase (G9a) and Histamine H3 Receptor for Prader-Willi Syndrome.
Sci. Rep. 2020, 10, 13558. (open access) doi.org/10.1038/s41598-020-70523-y.
Commented: https://www.newsbreak.com/news/1615451090494/epigenetics-meets-gpcr-inhibition-of-histone-h3-methyltransferase-g9a-and-histamine-h-receptor-for-praderwilli-syndrome

K. Szcepanska, A. Kincses, K. Vincze, E. Szymanska, G. Latacz, K. J. Kuder, H. Stark, G. Spengler, J. Handzlik, and K. Kiec-Kononowicz.
N-Substituted Piperazine Derivatives as Potential Multitarget Agents Acting on Histamine H3 Receptor and Cancer Resitance Proteins.
Bioorg. Med. Chem. Lett. 2020, 30, 127522. (doi: 10.106/j.bmcl2020.127522)

B. Stepanovska, A. Zivkovic, G. Enzmann, S. Tietz, T. Homann, B. Kleuser, B. Engelhardt, H. Stark, and A. Huwiler.
Morpholino Analogues of Fingolimod as Novel and Selective S1P1 Ligand with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis.
Int. J. Mol. Sci. 2020, 21, E6463. (open access) doi: 10.3390/ijms2118463.

N. Eissa, P. Jayaprakash, H. Stark, D. Lazewska, K. Kiec-Kononowicz, and B. Sadek.
Simultaneous Blockade of Histamine H3 Receptors and Inhibition of Acetylcholine Esterase Alleviate Autistic-like Behaviors in BTBR T+tf/J Mouse Model of Autism.
Biomolecules 2020, 10, E1251. (open access) doi:10.3390/biom10091251.

M. Grosicki, M. Adami, C. Micheloni, M. Gluch-Lutwin, A. Siwek, G. Latacz, D. Lazewska, M. Wiecek, D. Reiner-Link, H. Stark, S. Chlopicki, and K. Kiec-Kononowicz.
Eosinophils Adhesion Assay as a Tool for Phenotypic Drug Sccreening – The Pharmacology of 1,3,5-Triazine and 1H-Indole like Derivatives Against the Human Histamine H4 Receptor.
Eur. J. Pharmacol. 2020, 173611. DOI: 10.1016/j.ephar.2020.173611.

2019

A. P. Morris, T. H. Le, H. Wu, A. Akbarov, P. J. van der Most, G. Hemani, G. D. Smith, A. Mahajan, K. J. Gaulton, G. N. Nadkarni, A. Valladares-Salgado, N. Wacher-Rodarte, J. C. Mychaleckyj, N. D. Dueker, X. Guo, Y. Hai, J. Haessler, Y. Kamatani, A. M. Stilp, G. Zhu, J. P. Cook, J. Arnlov, S. H. Blanton, M. H. de Borst, E. P. Bottinger, T. A. Buchanan, S. Cechova, F. J. Charchar, P.-L. Chu, J. Damman, J. Eales, A. G. Gharavi, V. Giedraitis, A. C. Heath, E. Ipp, K. Kiryluk, M. Kubo, A. Larsson, C. M. Lindgren, Y. Lu, P. A. F. Madden, H. J. Mattix-Kramer, G. W. Montgomery, G. J. Papanicolaou, L. J. Raffel, R. L. Sacco, E. Sanchez, H. Stark, J. Sundstrom, K. D. Taylor, A. H. Xiang, A. Zivkovic, L. Lind, E. Ingelsson, N. G. Martin, J. B. Whitfield, J. Cai, C. C. Laurie, Y. Okada, K. Matsuda, C. Kooperberg, Y.-D. I. Chen, T. Rundek, S. S. Rich, R. J. F. Loos, E. J. Parra, M. Cruz, J. I. Rotter, H. Snieder, M. Tomaszewski, B. D. Humphreys, and N. Franceschini,    
on behalf of the Continental Origins and Genetic Epidemiology Network (COGENT) Kidney Consortium.
Trans-Ethnic Kidney Function Association Study Reveals Putative Causal Genes and Effects on Kidney-specific Disease Aetiologies.
Nat. Commun. 2019, 10(1):29. doi: 10.1038/s41467-018-07867-7 (open access).

E. Proschak, H. Stark, and D. Merk.
Polypharmacology by Design – A Medicinal Chemist´s Perspective on Multi-Targeting Compounds.
J. Med. Chem. 2019, 62, 420-444 .

. Ghamari, O. Zarei, D. Reiner, S. Dastmalchi, H. Stark*, and M. Hamzeh-Mivehroud*.
Histamine H3 Receptor Ligands By Hybrid Virtual Screening, Docking, Molecular Dynamics Simulations, and Investigation of Their Biological Effects.
Chem. Biol. Drug Des. 2019, 93, 832-843. doi: 10.1111/cbdd.13471.

D. Reiner and H. Stark.
Ligand Binding Kinetics at Histamine H3 Receptors by Fluorescence-Polarization with Real-time Monitoring.
Eur. J. Pharmacol. 2019, 848, 112-120.

C. Lanzi, L. Lucarini, M. Durante, S. Sgambellone, A. Pini, S. Catarinicchinia, D. Lazewska, K. Kiec-Kononowicz, H. Stark, and E. Masini.
Role of Histamine H3 Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma.
Int. J. Mol. Sci. 2019, 20 (4), 981; doi:10.3390/ijms20040981 (open access).
Selected for Medicine and Life Science 2019 Collection – WORD-APPLIED.

D. Łażewska, S. Mogilski, S. Hagenow, K. Kuder, M. Głuch-Lutwin, A. Siwek, M. Więcek, M. Kaleta, U. Seibel, A. Buschauer, B. Filipek, H. Stark, and K. Kieć-Kononowicz.
Alkyl Derivatives of 1,3,5-Triazine as Histamine H4 Receptor Ligands.
Bioorg. Med. Chem. 2019, 27(7), 1254-1262.

L. C. Pullen, M. Picone, L. Tan, C. Johnston, and H. Stark.
Cognitive Improvements in Children with Prader-Willi Syndrom Following Pitolisant Treatment – Patient Reports.
J. Pediatr. Pharmacol. Ther. 2019, 24(2), 166-171. (open access). doi: 10.5863/1551-6776-24.2.166.

A. Salem, R. Almahmoudi, T. Salo, J. Hagström, H. Stark, D. Nordström, and K. K. Eklund.
Histamine Regulates Human b-Defensin2 Expression in Oral Epithelium: Potential Therapeutic Targets in Oral Lichen Planus.
Int. J. Mol. Sci. 2019, 20, 1780; (open access). doi:10.3390/ijms20071780

D. Schaller, S. Hagenow, H. Stark, and G. Wolber.
Ligand-Guided Homology Modeling of Histamine H3 Receptor Drives Identification of New Antagonists.
PLOS One 2019, 14(6): e0218820. (open access) doi: 10.1371/journal.pone.0218820.

A. Sen, and H. Stark.
Role of Cytochrome P450 Polymorphisms and Functions in Development of Ulcerative Colitis.
World J. Gastroenterol. 2019, 25 (23), 2846-2862. (open access) doi: 10.3748/wjg.v25.i23.2846

N. Ghamari, O. Zarei, J.-A. Arias-Montano, D. Reiner, S. Dastmalchi, H. Stark*, and M. Hamzeh-Miveroud*.
Histamine H3 Receptor Antagonists/Inverse Agonists: Where Do They Go?
Pharmacol. Ther. 2019, 200, 69-84.

A. Frank, F. Meza-Arriagada, C. O. Salas, C. Espinosa-Bustos*, and H. Stark*.
Nature-inspired Pyrrolo[2,3-d]pyrimidines Targeting the Histamine H3 Receptor.
Bioorg. Med. Chem. 2019, 27, 3194-3200.

D. Drießen, F. Stuhldreier, A. Frank, H. Stark, S. Wesselborg, B. Stork, and T. J. J. Müller.
Novel Merolin Derivatives as Rapid Apoptosis Inducers.
Bioorg. Med. Chem. 2019, 27, 3463-3468.

K. Szczepańska, T. Karcz, A. Siwek, K. J. Kuder, G. Latacz, M. Bednarski, M. Szafarz, S. Hagenow, A. Lubelska, A. Olejarz-Maciej, M. Sobolewski, K. Mika, M. Kotańska, H. Stark, and Katarzyna Kieć-Kononowicz.
Structural Modifications and in vitro Pharmacological Evaluation of 4-Pyridyl-piperazine Derivatives as an Active and Selective Histamine H3 Receptor Ligands.
Bioorg. Chem. 2019, 91. 103071.

N. Eissa, S. Azimullah, P. Jayaprakash, R. L. Jayaraj, D. Reiner, S. K. Ojha, R. Beiram, H. Stark, D. Lazewska, K. Kiec-Konowicz, and B. Sadek.
The Dual-active Histamine H3 Receptor Antagonist and Acetylcholine Esterase Inhibitor E100 Ameliorates Stereotyped Repetitive Behavior and Neuroinflammmation in Sodium Valproate Induced Autism in Mice.
Chem. Biol. Interact. 2019, 312, 108775. (open access). doi: 10.1016/j.cbi.2019.108775

K. Lutsenko, S. Hagenow, A. Affini, D. Reiner, and H. Stark.
Rasagiline Derivatives Combined with Histamine H3 Receptor Properties.
Bioorg. Med. Chem. Lett. 2019, 29, 126612.

N. Porta, J. Schumacher, B. Frieg, M. Gopalswamy, A. Zivkovic, H. Stark, S. H. J. Smits, and H. Gohlke.
Small-Molecule Inhibitors of Nisin Resistence Protein NRS from Human Pathogen Streptococcus agalactica.
Bioorg. Med. Chem. 2019, 27, 115079.

C. Carbone, S. L. M. Lo Russo, E. Lacivita, A. Frank, E. Alleva, H. Stark, L. Saso, M. Leopoldo, and W. Adriani.
Prior Activation of 5-HT7 Receptors Modulates the Conditioned Place Preference with Methylphenidate.
Front. Behav. Neurosci. 2019, 13, 208. doi 10.3389/fnbeh.2019.00208 (open access)

P. Chazot, M. Cowart, H. Fukui, C. R. Ganellin, R. Gutzmer, H. L. Haas, S. J. Hill, R. Hills, R. Leurs, R. Levi, S. Liu, P. Panula, W. Schunack, J.-C. Schwartz, R. Seifert, N. P. Shankley, H. Stark, R. Thurmond, H. Timmerman, and J. M. Young.
Histamine Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database.
IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019 (4).
Available from: https://doi.org/10.2218/gtopdb/F33/2019.4

L. Stank, A. Frank, S. Hagenow, and H. Stark.
Talipexole Variations as Novel Bitopic Dopamine D2 and D3 Receptor Ligands.
MedChemComm. 2019, 10, 1926-1929.

E. Domínguez-Álvarez, D. Łażewska, Z. Szabó, S. Hagenow, D. Reiner, M. Gajdács, G. Spengler, H. Stark, J. Handzlik, and K. Kieć-Kononowicz.
The Search for Histamine H4 Receptor Ligands with Anticancer Activity Among Novel (Thio)Urea Derivatives.
ChemistrySelect 2019, 4 (36), 10943-10952. DOI: 10.1002/slct201902747

2018

H. Brückmann, A. Frank, D. Reiner, H. Stark.
Pharmakotherapie des Resteless-Legs-Syndroms – eine detaillierte Betrachtung.
Pharmacotherapy of RLS – A Detailed View.
Pharmakon 2018, 6, 35-47.

K. Popiolek-Barczyk, D. Łażewska, G. Latacz, A. Olejarz, W. Makuch, H. Stark, K. Kieć-Kononowicz, and J. Mika.
Antinociceptive Effects of Novel Histamine H3 and H4 Receptor Antagonists and Their Influence on Morphine Analgesia of Neuropathic Pain in the Mouse.
Br. J. Pharmacol. 2018, 175, 2897-2910.

A. Affini, S. Hagenow, A. Zivkovic, J. Marco-Contelles, and H. Stark.
Novel Indanone Derivatives as MAI B/H3R Dual Targeting Ligands for Treatment of Parkinson´s Disease.
Eur. J. Med. Chem. 2018, 148, 487-497.

S. Mommert, L. Ratz, H. Stark, R. Gutzmer, and T. Werfel.
The Histamine H4 Receptor Modulates the Differentiation Process of Human Monocyte-Derived M1 Macrophages and the Release of CCL4/MIP-1 from Fully Differentiated M1 Macrophages.
Inflamm. Res. 2018, 67 (6), 503-513.

A. Zivkovic, J. J. Bandolik, A. Skerhut, C. Coesfeld, and H. Stark.
NMR-basierte Lipophiliebestimmungen – Moderne Anwendungen der Instrumentellen Analytik.
PZ – Prisma 2018, 25, 26-30.

K. Szczepańska, T. Karcz, S. Mogilski, A. Siwek, K. J. Kuder, G. Latacz, S. Hagenow, A. Lubelska, A. Olejarz, M. Kotańska, B. Sadek, H. Stark, and K. Kieć-Kononowicz.
Synthesis and Biological Activity of Novel tert-Butyl and tert-Pentylphenoxyalkyl Piperazine Derivatives as Histamine H3R Antagonists.
Eur. J. Med. Chem. 2018, 152, 223-234.

D. Lazewska, M. Kaleta, S. Hagenow, S. Mogilski, G. Latacz, T. Karcz, A. Lubelska, E. Honkisz, J. Handzlik, D. Reiner, G. Satala, B. Filipek, H. Stark, and K. Kiec-Kononowicz.
Novel Naphthyloxy Derivatives – Potent Histamine H3 Receptor Ligands. Synthesis and Pharmacological Evaluation.
Bioorg. Med. Chem. 2018, 26, 2573-2585.

A. Alachkar, G. Latacz, A. Siwek, A. Lubelska, E. Honkisz, A. Grybos, D. Lazewska, J. Handzlik, H. Stark, K. Kiec-Kononowicz, and B. Sadek.
Anticonvulsant Evaluation of Novel Non-Imidazole Histamine H3R Antagonists in Different Convulsion Models in Rats.
Pharmacol. Biochem Behavior 2018, 170, 14-24.

H. Elshaflu, T. Todorović, M. Nikolić, A. Lolić, A. Višnjevac, S. Hagenow, J. M. Padrón, A. T. García-Sosa, I. S. Djordjević, S. Grubišić, H. Stark, and N. R. Filipovic.
Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies.
Front. Chem. – Med. Pharm. Chem. 2018, 247; doi.org/10.3389/fchem.2018.00247 (open access).

C. Espinosa-Bustos, A. Frank, S. Arancibia-Opazo, C. O. Salas, A. Fierro, and H. Stark.
New Lead Elements for Histamine H3 Receptor Ligands in the Pyrrolo[2,3-d]pyrimidine Class.
Bioorg. Med. Chem. Lett. 2018, 28, 2890-2893

M. A. Khanfar, D. Reiner, S. Hagenow, and H. Stark.
Design, Synthesis, and Biological Evaluation of Novel Oxadiazole- and Thiazole-Based Histamine H3R Ligands.
Bioorg. Med. Chem. 2018, 26, 4034-4046.

S. Mommert, D. Aslan, L. Ratz, H. Stark, R. Gutzmer, and T. Werfel.
The Anaphylatoxin C3a Receptor Expression on Human M2 Macrophages is Down-Regulated by Stimulating the Histamine H4 Receptor and the IL-4 Receptor.
J. Innate Immun. 2018, 10(4),349-362.

A. Frank, D. J. Kiss, G. J. Keserü, and H. Stark.
Binding Kinetics of Cariprazine and Aripiprazole at the Dopamine D3 Receptor.
Sci. Rep. 2018, 8(1), 12509. doi: 10.1038/s41598-018-30794-y. (open access).

M. Adami, C. Micheloni, D. Grandi, and H. Stark.
Differential Effects of Functionally Different Histamine H4 Receptor Ligands on Acute Irritant Dermatitis in Mice.
Naunyn Schmiedebergs Arch. Pharmacol. 2018, 391 (12), 1387-1397..

A. Alachkar, D. Łażewska, G. Latacz, A. Frank, A. Siwek, A. Lubelska, E. Honkisz-Orzechowska, J. Handzlik, H. Stark, K. Kieć-Kononowicz, and B. Sadek.
Studies on Anticonvulsant Effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in Rats.
Int. J. Mol. Sci. 2018, 19(11), pii: E3386. doi:103390/ijms19113386. (open access)

A. Stasiak, J. Gola, K. Kraszweska, M. Mussur, J. Kobos, U. Mazurek, H. Stark, and W. A. Fogel.
Experimental Autoimmune Myocarditis in Rats and Therapeutic H1-H4 Receptor Inhibition.
J. Physiol. Pharmacol. 2018, 69(6). 889-900. doi: 10.26402/jpp.2018.6.13 (open access)

K. Szczepanska, T. Karcz, M. Kotanska, A. Siwek, K. J. Kuder, G. Latacz, S. Moglinski, S. Hagenow, A. Lubelska, M. Sobolewski, H. Stark, and K. Kiec-Kononowicz.
Optimization and Preclinical Evaluation of Novel Histamine H3 Receptor Ligands: Acetyl and Propionyl Phenoxyalkyl Piperazine Derivatives.
Bioorg. Med. Chem. 2018, 26, 6056-6066.

2017

D. Vogt and H. Stark.
Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.
Med. Res. Rev. 2017, 37, 3-51. doi: 10.1002/med.21402
Cover page; Highlighted in Drug Week 2017,1 NewsRx p. 311.

S. B. M. Kretschmer, S. Woltersdorf, D. Vogt, A.-K. Häfner, F. F. Lillich, M. Rühl, M. Karas, A. Kaiser, M. Wurglics, M. Schubert-Zsilavecz, C. Angioni, G. Geisslinger, H. Stark, D. Steinhilber, and B. Hofmann.
Characterization of the Molecular Mechanism of 5-Lipoxygenase Inhibition by 2-Aminothiazoles.
Biochem. Pharmacol. 2017, 123, 52-62. doi: 10.1016/j.bcp.2016.09.021.

A. Zivkovic, J. J. Bandolik, A. J. Skerhut, C. Coesfeld, N. Zivkovic, M. Raos, and H. Stark.
Introducing Students to NMR Methods Using Low-Field 1H NMR Spectroscopy to Determine the Structure and the Identity of Natural Amino Acids.
J. Chem. Edu. 2017, 94, 115-120.

 A. Zivkovic, J. J. Bandolik, A.  J. Skerhut, C. Coesfeld, L. Zivkovic, M. Prascevic, L. Zivkovic, and H. Stark.
Quantitative Analysis of Multicomponent Mixtures of Over-the-Counter Pain Killer Drugs by Low-Field NMR Spectrometry.
J. Chem. Edu. 2017, 94, 121-125.

S. Hagenow, A. Stasiak, R. R. Ramsay, and H. Stark.
Ciproxifan, a Histamine H3 Receptor Antagonist, Reversibly Inhibits Monoamine Oxidase A and B.
Sci. Rep. 2017, 40541. (open access) doi: 10.1038/srep40541

J. M. Arencibia, W. Fröhner, M. Krupa, D. Pastor-Flores, P. Merker, T. Oellerich, S. Neimanis, C. Schmithals, V. Köberle, E. Süß, S. Zeuzem, H. Stark, A. Piiper, D. Odadzic, J. O. Schulze, and R. M. Biondi.
An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms.
ACS Chem. Biol. 2017, 12, 564-573.

K. Kuder, D. Lazewska, M. Kaleta, G. Latacz, T. Kottke, A. Olejarz, T. Karcz, A. Fruzinski, K. Szczepanska, J. Karolak-Wojciechowska, H. Stark, and K. Kiec-Kononowicz.
Synthesis and Biological Activity of Novel tert.-Amylphenoxyaminoalkyl (Homo)Piperidine Derivatives as Histamine H3R Ligands.
Bioorg. Med. Chem. 2017, 25, 2701-2712.

M. H. Sofi, J. Heinrichs, M. Dany, H. Nguyen, M. Dai, D. Bastian, S. Schutt, Y. Wu, A. Daenthanasanmak, S. Gencer, A. Zivkovic, Z. Szulc, H. Stark, C. Liu, Y.-J. Chang, B. Ogretmen, and X.-Z. Yu.
Ceramide Synthesis Regulates T-Cell Activity and GVDH Development.
JCI Insight 2017, 2(10), pii: 91701.  doi:10.1172/jci.insight.91701.

D. Schaller, S. Hagenow, G. Alpert, A. Naß, R. Schulz, M. Bermudez, H. Stark, and G. Wolber.
Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands.
ACS Med. Chem. Lett. 2017, 8, 648-653.

A. Frank, S. Abu-Lafib, A. Adawi, S. Schwed, H. Stark,* and A. Rayan.
From Medicinal Plants Extracts to Defined Chemical Compounds Targeting the Histamine H4 Receptor: Curcuma longa in the treatment of Inflammation.
Inflamm. Res. 2017, 66, 923-929.
Commented in ScienceTrends Oct. 20, 2017

Ó. M. Bautista-Aguilera, S. Hagenow, A. Palomino-Antolin, V. Farré-Alins, L. Ismaili, P.-L. Joffrin, M. L. Jimeno, O. Soukup, J. Janockova, L. Kalinowsky, E. Proschak, I. Iriepa, I. Moraleda, J. S. Schwed, A. R. Martinez, F. López-Muñoz, M. Chioua, J. Egea*, R. R. Ramsay, J. Marco-Contelles*, and H. Stark*.
Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases.
Angew. Chem. Int. Ed. 2017, 56, 12765-12769.

Multipotente Liganden mit kombinierter Cholinesterase- und Monoaminoxidase-Inhibition sowie Histamin-H3R-Antagonismus bei neurodegenerativen Erkrankungen.
Angew. Chem. 2017, 129, 12939-12943.
Selected as „hot paper“. Pressenotiz HHU 5.9.2017
ChemistryViews – Multitarget Drugs Fight Neurodegeneration (September 20, 2017)
Commented in ScienceTrends Oct. 30, 2017.

D. Lazewska, M. Kaleta, S. Schwed, T. Karcz, S. Mogilski, G. Latacz, A. Olejarz, A. Siwek, M. Kubacka, A. Lubelska, E. Honkisz, J. Handzlik, B. Filipek, H. Stark, and K. Kiec-Kononowicz.
Biphenyloxy-alkyl-piperidine and Azepane Derivatives as Histamine H3 Receptor Ligands.
Bioorg. Med. Chem. 2017, 25, 5341-5354. doi: 10.1016/j.bmc.2017.07.058

M. Schübler, B. Sadek, T. Kottke, L. Weizel, and H. Stark.
Synthesis, Molecular Properties Estimations and Dual D2 and D3 Receptor Activities of Benzthiazole-Based Ligands.
Front. Chem. 2017, 5, 64; doi 10.3389/fchem.2017.00064 (open access).

A. Zivkovic, J. J. Bandolik, A. J. Skerhut, C. Coesfeld, M. Raos, N. Zivkovic, V. Nikolic, and H. Stark.
Low Field NMR Determination of pKa Values for Hydrophylic Drugs for Students in Medicinal Chemistry.
Magnetochemistry 2017, 3, 29; doi:10.3390/magnetochemistry3030029

2016

B. Sadek and H. Stark.
Cherry-Picked Ligands at Histamine Receptor Subtypes.
Neuropharmacology 2016, 106, 56-73.

K. Kuder, D. Lazewska, G. Latacz, J. S. Schwed, T. Karcz, H. Stark, J. Karolak-Wojciechowska, and K. Kiec-Kononowicz.
Chlorophenoxy Aminoalkyl Derivatives as Histamine H3R Ligands and Antiseizure Agents.
Bioorg. Med. Chem 2016, 24, 53-72.

S. B. M. Kretschmer, S. Woltersdorf, C. B. Rödl, D. Vogt, A.-K. Häfner, D. Steinhilber, H. Stark and B. Hofmann.
Development of Novel Aminothiazole-comprising 5-Lipoxygenase Inhibitors.
Fut. Med. Chem. 2016, 8, 149-164.

M Capet, T. Calmels, N. Levoin, D. Danvy, I. Berriberi-Bertrand, H. Stark, J.-C. Schwartz and J.-M. Lecomte.
Improving Selectivity of Dopamine D3 Receptor Ligands.
Bioorg. Med. Chem. Lett. 2016, 26, 885-888.

R. Capelo, C. Lehmann, K. Ahmad, R. Snodgrass, O. Diehl, N. Flamand, A. Weigert, H. Stark, D. Steinhilber, and A. S. Kahnt.
Cellular Analysis of the Histamine H4 Receptor in Human Myeloid Cells.
Biochem. Pharmacol. 2016, 103, 74-84.

F. Imeri, S. Schwalm, R. Lyck, A. Zivkovic, H. Stark, B. Engelhardt, J. Pfeilschifter, and A. Huwiler.
Sphingosine Kinase 2 Deficient Mice Exhibit Reduced Experimental Autoimmune Encephalomyelitis: Resistance to FTY720 but not ST-968 Treatments.
Neuropharmacology 2016, 105, 341-350.

M. A. Khanfar, A. Affini, K. Lutsenko, K. Nikolic, S. Butini, and H. Stark.
Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.
Front. Neurosci. 2016, 10, 201; doi: 10.3389/fnins.2016.00201 (open access).

S. Mommert, S. Kleiner, M. Gehring, B. Eiz-Vesper, H. Stark, R. Gutzmer, T. Werfel, and U. Raap.
Human Basophil Chemotaxis and Activation Are Regulated via the Histamine H4 Receptor.
Allergy 2016, 71, 1264-1273. doi: 10.1111/all.12875

G. Latacz, P. Kechagioglou, R. Papi, D. Lazewska, M. Wiecek, K. Kaminska, P. Wencel, T. Karcz, J. S. Schwed, H. Stark, D. A. Kyriakidis, and K. Kiec-Kononowcz.
The Synthesis of 1,3,5-Triazine Derivatives and JNJ777120 Analogues with Histamine H4 Receptor Affinity and Their Interaction with PTEN Promoter.
Chem. Biol. Drug Des. 2016, 88, 254-263.

S. Butini, K. Nikolic, S. Kassel, H. Brückmann, S. Filipic, D. Agbaba, S. Gemma, S. Brogi, M. Brindisi, G. Campiani, and H. Stark.
Polypharmacology of Dopamine Receptor Ligands.
Prog. Neurobiol. 2016, 142, 68-103, doi: 10.1016/j.pneurobio.2016.03.011 (open access).

S. Ehling, K. Roßbach, S. M. Dunston, H. Stark, and W. Bäumer.
Allergic Inflammation Is Augmented via Histamine H4 Receptor Activation: The Role of Natural Killer Cells In Vivo and In Vitro.
J. Dermatol. Sci. 2016, 83, 106-115.

B. Sadek, A. Saad, A. Sadeq, F. Jalal, and H. Stark.
Histamine H3 Receptor as Potential Target for Cognitive Symptoms in Neuropsychiatric Diseases.
Behav. Brain Res. 2016, 312, 415-430. doi: 10.1016/j.bbr.2016.06.051

B. Sadek, A. Saad, J. S. Schwed, N. Khan, L. Weizel, M. Walter, and H. Stark.
Anticonvulsant Effects of Isomeric Nonimidazole Histamine H3 Receptor Antagonists.
Drug Des. Devel. Ther. 2016, 10, 3633-3651 (open access)

L. Lucarini, A. Pini, A. C. Rosa, C. Lanzi, M. Durante, P. L. Chazot, S. Krief, A. Schreeb, H. Stark, and E. Masini.
Role of Histamine H4 Receptor Ligands in Bleomycin-Induced Pulmonary Fibrosis.
Pharmacol. Res. 2016, 111, 740-748. doi: 10.1016/j.phrs.2016.07.037

K. Schaper, K. Rossbach, B. Köther, H. Stark, M. Kietzmann, T. Werfel, and R. Gutzmer.
Stimulation of the Histamine H4 Receptor Upregulates Thymic Stromal Lymphopoietin (TSLP) in Human and Mice Keratinocytes.
Pharmacol. Res. 2016, 113 (Pt A), 209-215. doi: 10.1016/j.phrs.2016.08.001

S. Maramai, S. Gemma, S. Brogi, G. Campiani, S. Butini, H. Stark, and M. Brindisi.
Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.
Front. Neurosci. 2016, 10, 451; doi: 10.3389/fnins.2016.00451 (open access).

B. Sadek, A. Saad, G. Latacz, K. Kuder, A. Olejarz, T. Karcz, H. Stark, and K. Kiec-Kononwicz.
Non-imidazole-based Histamine H3R Antagonists with Anticonvulsant Activity in Different Seizure Models in Male Adult Rats.
Drug Des. Devel. Ther. 2016, 10, 3879-3898 (open access)

2015

Y. Chen, V. Stagaev, V.-P. Kouri, T. Sillat, P. L. Chazot, H. Stark, J. G. Wen, and Y. T. Konttinen.
Identification of Histamine Receptor Subtypes in Skeletal Myogenisis..
Mol. Med. Rep. 2015, 11, 2624-2630 doi: 10.3892/mmr.2014.3073 (open access).

A. Lill, C. B. Rödl, D. Steinhilber, H. Stark, and B. Hofmann.
Development and Evaluation of ST-1829 Based on 5-Benzylidene-2-phenylthiazolones as Promising Agent for Anti-leukotriene Therapy.
Eur. J. Med. Chem. 2015, 89, 503-523.

A. Salem, A. Al-Samadi, V. Stegajev, H. Stark, R. Häyrinen-Immonen, M. Ainola, J. Hietanen, and Y. T. Konttinen.
Histamine H4 Receptor in Oral Lichen Planus.
Oral Dis. 2015, 21, 378-385.

K. Nikolic, D. Agbaba, and H. Stark.
Pharmacophore Modeling, Drug Design and Virtual Screening on Multi-Targeting Procognitive Agents Approaching Histaminergic Pathways.
J. Taiwan. Inst. Chem. E. 2015, 46, 15-29.

M. Feliszek, V. Speckmann, D. Schacht, M. von Lehe, H. Stark, and E. Schlicker.
A Search for Functional Histamine H4 Receptors in the Human, Guinea-pig and Mouse Brain.
Naunyn Schmiedeberg´s Arch. Pharmacol. 2015, 388, 11-17.

S. Kassel, J. S. Schwed, and H. Stark.
Dopamine D3 Receptor Agonists as Pharmacological Tools.
Eur. Neuropsychopharmacol. 2015, 25, 1480-1499.

S. Kaßel, J. Hagenow und H. Stark.
H1-Antihistaminika – Aktuelle Aspekte einer alten Arzneistoffgruppe.
H1-Antihistamines – Actual Aspects of an Old Class of Drugs]
Pharmakon 2015, 2(2), 96-108.

K. Nikolic, L. Mavridis, O. M. Bautista-Aguilera, J. Marco-Contelles, H. Stark; M. do Carmo Carreiras, I. Rossi, P. Massarelli, D. Agbaba, R. R.Ramsey, and J. B. O. Mitchell.
Predicting Targets of Multipotent Compounds against Neurological Diseases Using Cheminformatic Methodology.
J. Comp. Aided Mol. Des. 2015, 29, 183-198.

Y. Chen, J. Paavola, V. Stegaev, H. Stark, P. L. Chazot, J. G. Wen, and Y. T. Konttinen.
Activation of Histamine H3 Receptor Decreased Cytoplasmatic Ca2+ Imaging during Electrical Stimulation in the Skeletal Myotubes.
Eur. J. Pharmacol. 2015, 754, 173-178.

S. Mommert, O. Dittrich-Breiholz, H. Stark, R. Gutzmer, and T. Werfel.
The Histamine H4 Receptor Regulates Chemokine Production in Human Natural Killer Cells.
Int. Arch. Allergy Imm. 2015, 166, 225-230.

D. D. Zhang, B. Linke, J. Suo, A. Zivkovic, Y. Schreiber, N. Ferreios, M. Henke, G. Geisslinger, H. Stark, and K. Scholich.
Antinociceptive Effects of FTY720 during Trauma-induced Neuropathic Pain are Mediated by Spinal S1P Receptors.
Biol. Chem. 2015, 396, 783-794.

P. Panula, P. L. Chazot, M. Cowart, R. Gutzmer, R. Leurs, W. L.S. Liu, H. Stark, R. L. Thurmond, and H. L. Haas.
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
Pharmacol. Rev. 2015, 67, 601-655.

D. Flesch, M. Gabler, A. Lill, R. Carrasco Gomez, R. Steri, G. Schneider, H. Stark, M. Schubert-Zsilavecz, and D. Merk.
Fragmentation of GW4064 Led to the Discovery of Highly Potent Partial Farnesoid X Receptor Agonist with Improved Drug-like Properties.
Bioorg. Med. Chem. 2015, 23, 3490-3498.

J. Hagenow and H. Stark.
Histamine H4 Receptor Antagonists: A New Approach for Tinnitus Treatment? Rec. Pat. CNS Drug Disc. 2015, 10, 6-9.

M.-C. Scherzberg, A. Kiehl, A. Zivkovic, H. Stark, J. Stein, R. Fürst, D. Steinhilber, and S. Ullrich-Rückert.
Structural Modification of Resveratrol Leads to Increased Anti-tumor Activity, but Causes Profound Changes in the Mode of Action.
Toxicol. Appl. Pharm. 2015, 287, 67-76.

K. Sander, E. Galante, T. Gendron, E. Yiannaki, N. Patel, T. L. Kalber, A. Badar, M. Robson, S. P. Johnson, F. Bauer, S. Mairinger, J. Stanek, T. Wanek, C. Kuntner, T. Kottke, L. Weizel, D. Dickens, K. Erlandsson, B. F. Hutton, M. F. Lythgoe, H. Stark, O. Langer, M. Koepp, and E. Årstad.
Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with PET.
J. Med. Chem. 2015, 58, 6058-6080.

F. Imeri, C. Wünsche, u.a. A. Zivkovic, H. Stark, J. Pfeilschifter, and A. Huwiler.
FTY720 and Two Novel Butterfly Derivatives Exert a General Anti-inflammatory Potential by Reducing Immune Cell Adhesion to Endothelial Cells Through Activation of S1P3 and Phosphatidylinositide 3'-kinase .
Naunyn Schmiedebergs Arch. Pharmacol. 2015, 388, 1283-1292.

M. D. Sanna, H. Stark, L. Lucarini, C. Ghelardini, E. Masini, and N. Galeotti.
Histamine H4 Receptor Activation Alleviates Neuropathic Pain through Differential Regulation of ERK, JNK and P38 MAPK Phosphorylation.
Pain 2015, 156, 2492-2504.

 

K. Kaminska, J. Ziemba, J. Ner, J. S. Schwed, D. Lazewska, M. Wiecek, T. Karcz, G. Latacz, K. Kuder, T. Kottke, M. Zygmunt, J. Sapa, J. Karolak-Wojciechowska, H. Stark, and K. Kiec-Kononowicz.
(2-Arylethenyl)-1,3,5-triazine-2-amines as Novel Histamine H4 Receptor Ligands.
Eur. J. Med. Chem. 2015, 103, 238-251

2014

F. Glatzer, S. Mommert, B. Köther, M. Gschwandtner, H. Stark, T. Werfel, and R. Gutzmer.
Histamine Downregulates the Th1-Associated Chemokine IP-10 in Monocytes and Myeloid Dendritic Cells.
Int. Arch. Allergy Imm. 2014, 163, 11-19.

D. Vogt und H. Stark.
Arzneistoffe in der Pharmakotherapie der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (Drugs for Medical Treatment of ADHD).
Pharmakon- Arzneimittel in Wissenschaft und Praxis 2014, 2, 26-36.

B. Sadek, J. S. Schwed, D. Subramanian, L. Weizel, M. Walter, A. Adem, and H. Stark.
Non-imidazole Histamine H3 Receptor Ligands Incorporating Antiepileptic Moieties.
Eur. J. Med. Chem. 2014, 77, 269-279.

G. M. Leggio, G. Cammillieri, C. B. M. Platania, A. Castorina, G. Marrazzo, S. A. Torrisi, C. N. Nona, V. D´Ágata, J. Nobrega, H. Stark, C. Bucolo, B. Le Foll, F. Drago, and S. Salomone.
Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone.
Neuropsychopharmacology 2014, 39, 2017-2028 (open access).

A. Bahi, J. S. Schwed, M. Walter, H. Stark, and B. Sadek.
Anxiolytic and Antidepressant-like Properties of the Novel and Potent Non-imidazole Histamine H3 Receptor Antagonist ST-1283.
Drug Des. Develop Ther. 2014, 8, 627-637 (open access).

B. Sadek, K. Kuder, D. Subramanian, M. Shafiullah, H. Stark, D. Lazewska, A. Adem, and K. Kiec-Kononowicz.
Anticonvulsive Effect of Non-imidazole Histamine H3 Receptor Antagonists.
Behav. Pharmacol. 2014, 25, 245-252.

K. Wingen, J. S. Schwed, K. Isensee, L. Weizel, A. Zivkovic, D. Odadzic, and H. Stark.
Benzylpiperidine Variations on Histamine H3 Receptor Ligands for Improved Drug-likeness.
Bioorg. Med. Chem. Lett. 2014, 24, 2236-2239.
Corrigendum: Bioorg. Med. Chem. Lett. 2014, 25, 2972.

H. Zhang, S. Neimanis, L. A. Lopez-Garcia, J. M. Arencibia, S. Amon, A. Stroba, S. Zeuzem, E. Proschak, H. Stark, A. F. Bauer, K. Busschots, T. J. D. Jørgensen, M. Engel, J. O. Schulz, and R. M. Biondi.
Molecular Mechanism of Regulation of the Atypical Protein Kinase C (aPKC) by N-Terminal Domains and Allosteric Small Compounds.
Chem. Biol. 2014, 21, 745-765.

K. Nikolic, S. Filipic, D. Agbaba, and H. Stark.
Procognitive Properties of Drugs with Single and Multitargeting Histamine H3 Receptor Antagonist Activities.
CNS Neurosci. Therap. 2014, 20, 613-623.

F. Imeri, D. Fallegger, A. Zivkovic, S. Schwalm, G. Enzmann, K. Blankenbach, D. Meyer zu Heringdorf, T. Homann, B. Kleuser, J. Pfeilschifter, B. Engelhardt, H. Stark, and A. Huwiler.
Novel Oxazolo-oxazole Derivatives of FTY720 Reduce Endothelial Cell Permeability, Immune Cell Chemotaxis and Symptoms of Experimental Autoimmune Encephalomyelitis in Mice.
Neuropharmacology 2014, 85, 314-327.

D. Lazewska, M. Wiecek, J. Ner, K. Kaminska, T. Kottke, J. S. Schwed, M. Zygmunt, T. Karcz, A. Olejarz, K. Kuder, G. Latacz, M. Grosicki, J. Sapa, J. Karolak-Wojciechowska, H. Stark, and K. Kiec-Kononowicz.
Aryl-1,3,5-triazine Derivatives as Histamine H4 Receptor Ligands.
Eur. J. Med. Chem. 2014, 83, 534-546.

C. B. Rödl*, D. Vogt*, S. B. M. Kretschmer, K. Ihlefeld, S. Barzen, A. Brüggerhoff, J. Achenbach, E. Proschak, D. Steinhilber, H. Stark#, and B. Hofmann#.
Multi-Dimensional Target Profiling of N,4-Diaryl-1,3-thiazole-2-amines as Potent Inhibitors of Eicosanoid Metabolism.
Eur. J. Med. Chem. 2014, 84, 302-311.

B. Sadek, A. Schreeb, J. S. Schwed, L. Weizel, and H. Stark.
Drug-Likeness Approach on 2-Aminopyrimidines as Histamine H3 Receptor Ligands.
Drug Des. Devlop Ther. 2014, 8, 1499-1513 (open access).

D. Vogt, J. Weber, K. Ihlefeld, A. Brüggerhoff, E. Proschak, and H. Stark.
Design, Synthesis and Evaluation of 2-Aminothiazole Derivatives as Sphingosine Kinase Inhibitors.
Bioorg. Med. Chem. 2014, 22, 5354-5367.

A. C. Rosa, A. Pini, L. Lucarini, C. Lanzi, E. Vegilia, R. L. Thurmond, H. Stark, and E. Masini.
Prevention of Bleomycin-Induced Lung Inflammation and Fibrosis in Mice by Naproxen and JNJ7777120 Treatment.
J. Pharmacol. Exp. Ther. 2014, 351, 308-316 (open access).

L. Lipani, D. Odadzic, L. Weizel, J. S. Schwed, B. Sadek, and H. Stark.
Studies on Molecular Properties Prediction and Histamine H3 Receptor Affinities of Novel Ligands with Uracil-based Motifs.
Eur. J. Med. Chem. 2014, 86, 578-588

 

K. Rüger, F. Ottenlinger, M. Schröder, A. Živković, H. Stark, J. M. Pfeilschifter, and H. H. Radeke
Modulation of IL-33/ST2-TIR and TLR Signaling Pathway by Fingolimod and Analogs in Immune Cells.
Scand. J. Immunol. 2014, 80, 398-407.

V. Stegajev, V.-P. Kouri, A. Salem, S. Rozov, H. Stark, D. E. C. Nordström, and Y. T. Konttinen.
Activation of Histamine H4 Receptor Inhibits TNF-a/IMD-0354-induced Apoptosis in Human Salivary NS-SV-AC Cells.
Apoptosis, 2014, 19, 1702-1711.

S. Schumacher, M. Kietzmannm, H. Stark, and W. Bäumer.
Unique Immunmodulatory Effects of Azelastine on Dendritic Cells in vitro.
Naunyn Schmiedebergs Arch. Pharmacol. 2014, 387, 1091-1099.

2013

A. Paulke, C. Kremer, C. Wunder, J. Achenbach, B. Djahanschiri, A. Elias, J. S. Schwed, H. Hübner, P. Gmeiner, E. Proschak, S. W. Toennes, and H. Stark.
Argyreia nervosa (Burm. f.): Receptor Profiling of Lysergic Acid Amide and other potential Psychedelic LSD-like Compounds by Computational and Binding Assay Approaches.
J. Ethnopharmacol. 2013, 148, 492-497.

E.la Buscato, D. Büttner, A. Brüggerhoff, F.-M. Klingler, J. Weber, B. Scholz, A. Zivkovic, R. Marschalek, H. Stark, D. Steinhilber, H. B. Bode and E. Proschak.
From a Multipotent Stilbene to Soluble Epoxide Hydroxylase Inhibitors with Antiproliferative Properties.
ChemMedChem 2013, 8, 919-923. (Front cover)

A. Bahi, J. S. Schwed, M. Walter, H. Stark, and B. Sadek,.
Influence of the Novel Histamine H3 Receptor Antagonist ST1283 on Voluntary Alcohol Consumption and Ethanol-induced Place Preference in Mice.
Psychopharmacol. 2013, 228, 85-95.

A. Schreeb, M. Walter, D. Odazic, J. S. Schwed, L. Weizel, and H. Stark.
Piperazine Modifications in 2,4,6-Triaminopyrimidine Derivatives as Histamine H4 Receptor Ligands.
Pharmazie 2013, 68, 521-525.

A. E. Loot, I. Pierson, T. Syzonenko, A. Elgheznawy, V. Randriamboavonjy, A. Zivkovic, H. Stark, and I. Fleming.
Ca2+-sensing Receptor Cleavage by Calpain Partially Accounts for Altered Vascular Reactivity in Mice Fed a High-fat Diet.
J. Cardiovasc. Pharmacol. 2013, 61, 528-535.

M. Tomasch, J. S. Schwed, A. Paulke, and H. Stark.
Bodilisant – A Novel Fluorescent, Highly Affine Histamine H3 Receptor Ligand.
ACS Med. Chem. Lett. 2013, 4, 269-273.

S. Greco, W. Danysz, A. Zivkovic, R. Groß, and H. Stark.
Microdialysate Analysis of Monoamine Neurotransmitters – A Versatile and Sensitive LC-MS/MS Method.
Anal. Chim. Acta 2013, 771, 65-72.

L.-J. Gao, J. S. Schwed, L. Weizel, S. De Jonghe, H. Stark, and P. Herdewijn.
Synthesis and Evaluation of Novel Ligands for the Histamine H4 Receptor Based on a Pyrrolo[2,3-d]pyrimidine Scaffold.
Bioorg. Med. Chem. Lett. 2013, 23, 132-137.

M. Gschwandtner, B. Köther, T. Werfel, H. Stark, and R. Gutzmer.
Profiling of Histamine H4 Receptor Agonists in Native Human Monocytes.
Br. J. Pharmacol. 2013, 170, 136-143.

U. Nordemann, D. Wifling, D. Schnell, G. Bernhardt, H. Stark, R. Seifert, and A. Buschauer
Luciferase Reporter Gene Assay on Human, Murine and Rat Histamine H4 Receptor Orthologs: Correlations and Discrepancies between Distal and Proximal Readouts.
PLoS ONE 2013, 8(9): e73961. doi:10.1371/journal.pone.0073961.

K. Wingen and H. Stark.
Scaffold Variations in Amine Warhead of Histamine H3 Receptor Antagonists.
Drug Disc. Today Techn. 2013, 10(4), e483-e489.

A. Lill, K. Scholich, and H. Stark.
Synthesis of Novel Dansyl-Labeled Celecoxib Derivatives.
Tetrahedron Lett. 2013, 54(49), 6682-6686.

S. Micallef, H. Stark, and A. Sasse.
Polymorphism and Genetic Linkage of Histamine Receptors.
Life Sci. 2013, 93, 487-494.

A. Babelova, F. Jansen, K. Sander, M. Löhn, L. Schäfer, C. Fork, H. Rütten, O. Plettenburg, H. Stark, C. Daniel, K. Amann, H. Pavenstädt, O. Jung, and R. P. Brandes..
Activation of Rac-1 and RhoA Contributes to Podocyte Injury in Chronic Kidney Disease.
PLoS ONE 2013, 8(11), e80328; doi: 10.1371/journal.pone.0080328.

J. Achenbach, F.-M. Klingler, R. Blöcher, D. Moser, A.-K. Häfner, C. B. Rödl, S. Kretschmer, B. Krüger, F. Löhr, H. Stark, B. Hofmann, D. Steinhilber, and E. Proschak.
Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps.
ACS Med. Chem. Lett. 2013, 4, 1169-1172.

2012

S. Schiffmann, D. Hartmann, S. Fuchs, K. Birod, N. Ferreiròs, Y. Schreiber, A. Zivkovic, G. Geisslinger, S. Grösch, and H. Stark.
Inhibitors of Specific Ceramide Synthases.
Biochimie 2012, 94, 558-565.

M. Walter and H. Stark.
Histamine Receptor Subtypes: A Century of Rational Drug Design.
Front. Biosci. (Schol. Ed.) 2012, S4, 461-488. (Review)

B. Hofmann, C. B. Rödl, A. S. Kahnt, T. J. Maier, A. A. Michel, M. Hoffmann, O. Rau, K. Awwad, M. Pellowska, M. Wurglics, M. Wacker, A. Zivkovic, I. Fleming, M. Schubert-Zsilavecz, H. Stark, G. Schneider, and D. Steinhilber.
Molecular Pharmacological Profile of a Novel Thiazolinone-Based Direct and Selective 5-Lipoxygenase Inhibitor.
Br. J. Pharmacol. 2012, 165, 2304-2313.
Selected for special communication by Global Medical Discovery: globalmedicaldiscovery.com/key-scientific-articles/molecular-pharmacological-profile-of-a-novel-thiazolinone-based-direct-and-selective-5-lipoxygenase-inhibitor/

M. Hartenfeller, H. Zettl, M. Walter, M. Rupp, F. Reisen, E. Proschak, S. Weggen, H. Stark, and G. Schneider.
DOGS: Reaction-driven de novo Design of Bioactive Compounds.
PloS Comp. Biol. 2012, 8(2), e1002380.     doi:101371/journal.pcbi.1002380 (open access)

V. Stegaev, T. Sillat, P. Porola, A. Hänninen, A. Falus, D. Mieliauskaite, E. Buzas, Z. Rotar, Z. Mackiewicz, H. Stark, P. L. Chazot and Y. T. Konttinen.
Brief Report: First Identification of H4 Histamine Receptor in Healthy Salivary Glands and in Focal Sialadenitis in Sjögren´s Syndrome.
Arthritis Rheum. 2012, 64, 2663-2668.

M. Tomasch, J. S. Schwed, L. Weizel, and H. Stark.
Novel Chalcone-based Fluorescent Human Histamine H3 Receptor Ligands as Pharmacological Tools.
Front. Syst. Neurosci. 2012, 6/14.     doi: 10.3389/fnsys.2012.00014 (open access).

D. D. Zhang, M. Sisignano, C. D. Schuh, K. Sander, H. Stark, and K. Scholich.
Overdose of the Histamine H3 Receptor Antagonist Pitolisant Increases Thermal Pain Thresholds.
Inflamm. Res. 2012, 61(11). 1283-1291.

S. Barzen, C. B. Rödl, A. Lill, D. Steinhilber, H. Stark, and B. Hofmann.
Synthesis and Biological Evaluation of a Class of 5-Benzyliden-2-phenyl-thiazolinones as Potent 5-Lipoxygenase Inhibitors.
Bioorg. Med. Chem. 2012, 20, 3575-3583.

M. Hieke, C. B. Rödl, J. M. Wisnieswska, E.la Buscató, H. Stark, M. Schubert-Zsilavecz, D. Steinhilber, B. Hofmann, and E. Proschak.
SAR-Study on a New Class of Imidazo[1,2-a]pyridine-based Inhibitors of 5-Lipoxygenase.
Bioorg. Med. Chem. Lett. 2012, 22, 1969-1975.

M. Tomasch, J. S. Schwed, K. Kuczka, S. Meyer dos Santos, S. Harder, R. M. Nüsing, A. Paulke, and H. Stark.
Fluorescent Human EP3 Receptor Antagonists.
ACS Med. Chem. Lett. 2012, 3, 774-779.

S. V. Selivanova, M. Honer, F. Combe, K. Isensee, H. Stark, S. D. Krämer, P. A. Schubiger, and S. M. Ametamey.
Radiofluorinated Histamine H3 Receptor Antagonist as a Potential Probe for In Vivo PET Imaging: Radiosynthesis and Pharmacological Evaluation.
Bioorg. Med. Chem. 2012, 20, 2889-2896.

2011

T. Kottke, K. Sander, L. Weizel, E. H. Schneider, R. Seifert, and H. Stark.
Receptor-Specific Functional Efficacies of Alkyl Imidazoles as Dual Histamine H3/H4 Receptor Ligands.
Eur. J. Pharmacol. 2011, 654, 200-208.

K. Rossbach, C. Nassenstein, M. Gschwandtner, D. Schnell, K. Sander, R. Seifert, H. Stark, M. Kietzmann, and W. Bäumer.
Histamine H1, H3 and H4 Receptors Are Involved in Pruritus.
Neuroscience 2011, 190, 89-102.

W. Bäumer, J. Stahl. K. Sander, L. Petersen, J. Paps, H. Stark, M. Kietzmann, and T. Olivry.
Lack of Preventing Effect of Systemically and Topically Administered Histamine H1 or H4 Receptor Antagonists in a Dog Model of Acute Atopic Dermatitis.
Exp. Dermatol. 2011, 20, 577-581.     doi: 10.1111/j.1600-0625.2011.01268.x

B. Hofmann, S. Barzen, C. B. Rödl, A. Kiehl, J. Borig, A. Zivkovic, H. Stark, G. Schneider, and D. Steinhilber.
A Class of 5-Benzylidene-2-phenyl-thiazolinones with High Potency as Direct 5-Lipoxygenase Inhibitors.
J. Med. Chem. 2011, 54, 1943-1947.
Selected for special communication with www.nature.com/SciBX (4(11);     doi:10.1038/scibx.2011.322

M. Wiecek, T. Kottke, X. Ligneau, W. Schunack, R. Seifert, H. Stark, J. Handzlik, and K. Kiec-Konowicz.
N-Alkenyl and Cycloalkyl Carbamates as Dual Acting Histamine H3 and H4 Receptor Ligands.
Bioorg. Med. Chem. 2011, 19, 2850-2858.

M. Walter, T. Kottke, and H. Stark.
Perspective: The Histamine H4 Receptor: Targeting Inflammatory Diseases.
Eur. J. Pharmacol. 2011, 668, 1 – 5.

M. Walter, T. Kottke, L. Weizel, J. S. Schwed, and H. Stark.
Synthesis of 1,2,3-Triazole Elements in Histamine H3 Receptor Ligands.
Synthesis 2011, 17, 2733-2736.

2010

K. Sander, Y. von Coburg, J.-C. Camelin, X. Ligneau, O. Rau, M. Schubert-Zsilavecz, J.-C. Schwartz, and H. Stark.
Acidic Elements in Histamine H3 Receptor Antagonists.
Bioorg. Med. Chem. Lett. 2010, 20, 1581-1584.

M. Geschwandtner, K. Rossbach, W. Bäumer, M. Kietzmann, D. Dijkstra, H. Stark, T. Werfel, and R. Gutzmer.
Murine and Human Langerhans Cells Express a Functional Histamine H4 Receptor: Modulation of Cell Migration and Function.
Allergy, 2010, 65, 840-849.

K. Sander, T. Kottke, E. Proschak, Y. Tanrikulu, E. H. Schneider, R. Seifert, G. Schneider, and H. Stark.
Lead Identification and Optimization of Diaminopyrimidines as Histamine H4 Receptor Ligands.
Inflamm. Res. 2010, 59 (Suppl.), S249 – S251.

K. J. Kuder, T. Kottke, H. Stark, X. Ligneau, J.-C. Camelin, R. Seifert, and K. Kieć- Kononowicz.
Search for Novel, Highly Affine Histamine H3 Receptor Ligands with Fluorescent Properties.
Inflamm. Res. 2010, 59 (Suppl.), S247 – S248.

A. Zivkovic and H. Stark.
Efficient Chromatography-Free Synthesis of the Oxy Analogue of Fingolimod.
Tetrahedron Lett. 2010, 51, 3769-3771.

K. Sander, T. Kottke, C. Hoffend, L. Weizel, J.-C. Camelin, X. Ligneau, E. H. Schneider, R. Seifert, J.-C. Schwartz, and H. Stark.
First Metal-Containing Histamine H3 Receptor Ligands.
Org. Lett. 2010, 12, 2578-2581.
Selected for Faculty of 1000 Biology: recommended paper, factor 3.0 (id/3386958).

T. Werner, K. Sander, Y. Tanrikulu, T. Kottke, E. Proschak, H. Stark, and G. Schneider.
In Silico Characterization of Different Ligand Binding Modes in the Human Histamine H4 Receptor and Their Impact on Receptor Activation.
ChemBioChem, 2010, 11, 1850-1855.

K. Sander, T. Kottke, L. Weizel, and H. Stark.
Kojic Acid Derivatives as Histamine H3 Receptor Ligands.
Chem. Pharm. Bull. 2010, 58(10), 1353-1361.

M. Walter, Y. von Coburg, K. Isensee, K. Sander, X. Ligneau, J.-C. Camelin, J.-C. Schwartz, and H. Stark.
Azole Derivatives as Histamine H3 Receptor Antagonists, Part 1: Thiazol-2-yl Ethers.
Bioorg. Med. Chem. Lett. 2010, 20, 5879-5882.

M. Walter, K. Isensee, T. Kottke, X. Ligneau, J.-C. Camelin, J.-C. Schwartz, and H. Stark.
Azole Derivatives as Histamine H3 Receptor Antagonists, Part 2: C-C and C-S Coupled Heterocycles.
Bioorg. Med. Chem. Lett. 2010, 20, 5883-5886.

M. Adami, C. Pozzoli, R. Leurs, H. Stark, and G. Coruzzi.
Histamine H3 Receptors Are Involved in the Protective Effect of Ghrelin against HCl-Induced Gastric Damage in Rats.
Pharmacol. 2010, 86, 259-266.

2009

K. Roßbach, S. Wendorff, K. Sander, H. Stark, R. Gutzmer, T. Werfel, M. Kietzmann, and W. Bäumer.
Histamine H4 Receptor Antagonism Reduces Hapten-Induced Scratching Behaviour but not Inflammation.
Exp. Dermatol. 2009, 18, 57-63.

E. Proschak, K. Sander, H. Zettl, Y. Tanrikulu, O. Rau, P. Schneider, M. Schubert-Zsilavecz, H. Stark and G. Schneider.
From Molecular Shape to Potent Bioactive Agents II: Fragment-Based de novo Design.
ChemMedChem 2009, 4, 45-48.

K. J. Kuder, X. Ligneau, J.-C. Camelin, D. Lazeska, J.-C. Schwartz, W. Schunack, H. Stark, and K. Kiec-Kononowiecz.
Diether (Substituted)piperidine Derivatives as Novel Active Histamine H3 Receptor Ligands.
Inflamm. Res. 2009, 58 (Suppl. 1), S47-S48.

R. Gutzmer, S. Mommert, M. Gschwandtner, K. Zwingmann, H. Stark, and T. Werfel.
The Histamine H4 Receptor is Functionally Expressed on Th2 Cells.
J. Allergy Clin. Invest. 2009, 123, 619-625.

Y. von Coburg, T. Kottke, L. Weizel, X. Ligneau, and H. Stark.
Potential Utility of Histamine H3 Receptor Antagonist Pharmacophore in Antipsychotics.
Bioorg. Med. Chem. Lett. 2009, 19, 538-542.

K. Roßbach, H. Stark, K. Sander, R. Leurs, M. Kietzmann, and W. Bäumer.
The Histamine H4 Receptor as a New Target for Treatment of Canine Inflammatory Skin Disease.
Vet. Dermatol. 2009, 20, 555-561.

D. Lazewska, K. Kuder, X. Ligneau, J.-C. Camelin, W. Schunack, H. Stark, and K. Kiec-Kononowicz.
Diether Derivatives of Homo- or Substituted Piperidines as Non-Imidazole Histamine H3 Receptor Ligands.
Bioorg. Med. Chem. 2009, 17, 3037-42.

Y. Tanrikulu, E. Proschak, T. Werner, T. Geppert, N. Todoroff, A. Klenner, T. Kottke, K. Sander, E. Schneider, R. Seifert, H. Stark, T. Clark, and G. Schneider.
Homology Model Adjustment and Ligand Screening with a Pseudoreceptor of the Human Histamine H4 Receptor.
ChemMedChem 2009, 4, 820-827.
ChemMedChem 2009, 4, 694 (inside cover).

A. Berthet, G. Porras, E. Doudnikoff, H. Stark, M. Cador, E. Bezard, and B. Bloch.
Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L-DOPA-Induced Dyskinesia.
J. Neurosci. 2009, 29, 4829-4835.

K. Isensee, M. Amon, A. Garlaparti, X. Ligneau, J.-C. Camelin, M. Capet, J.-C. Schwartz, and H. Stark.
Fluorinated Non-Imidazole Histamine H3 Receptor Antagonists.
Bioorg. Med. Chem. Lett. 2009, 19, 2172-2175; Erratum 2009, 19, 3348.

E. Tiligada, E. Zampeli, K. Sander, and H. Stark.
Investigational Agents for Targeting Histamine H3 and H4 Receptors.
Expert Opin. Investig. Drugs 2009, 18, 1519-1531.

K. Sander, T. Kottke, E. Proschak, Y. Tanrikulu, L. Weizel, E. H. Schneider, R. Seifert, G. Schneider, and H. Stark.
Diaminopyrimidines as Histamine H4 Receptor Ligands – Lead Structure Identification by Virtual Screening and Scaffold Optimization.
Bioorg. Med. Chem. 2009, 17, 7186-7196.

D. Łażewska, M. Więcek, X. Ligneau, T. Kottke, L. Weizel, R. Seifert, W. Schunack, H. Stark, and K. Kieć-Kononowicz.
Histamine H3 and H4 Receptor Affinity of Branched 3-(1H-Imidazol-4-yl)propyl N-alkylcarbamates.
Bioorg. Med. Chem. Lett. 2009, 19, 6682-6685.

2008

D. Dijkstra, H. Stark, P. L. Chazot, F. C. Shenton, R. Leurs, T. Werfel, and R. Gutzmer.
Human Inflammatory Dendritic Epidermal Cells Express a Functional Histamine H4 Receptor.
J. Invest. Dermatol. 2008, 128, 1696-1703.

D. Lazewska, K. Kuder, X. Ligneau, J.-C. Schwartz, W. Schunack, H. Stark, and K. Kiec-Kononowicz.
Piperidine Variations in Search for Non-Imidazole Histamine H3 Receptor Ligands.
Bioorg. Med. Chem. 2008, 16, 8729-8736.

W. Bäumer, S. Wendorff, R. Gutzmer, T. Werfel, D. Dijkstra, P. Chazot, F. C. Shenton, H. Stark, and M. Kietzmann.
Histamine H4 Receptors Modulate Dendritic Cell Migration through Skin – Immunomodulatory Role of Histamine.
Allergy 2008, 63, 1387-1394.

N. Levoin, T. Calmels, O. Poupardin-Olivier, O. Labeeuw, D. Danvy, P. Robert, I. Berrebi-Bertrand, C.R. Ganellin, W. Schunack, H. Stark, and M. Capet.
Refined Docking as a Valuable Tool for Lead Optimization: Application to Histamine H3 Receptor Antagonists.
Arch. Pharm. 2008, 341, 610-623.

K. Sander, T. Kottke, and H. Stark.
Histamine H3 Receptor Antagonists Go to Clinics.
Biol. Pharm. Bull. 2008, 31, 2163-2181.

K. Sander, H. Zettl, M. Schubert-Zsilavecz und H. Stark.
Medizinische Chemie von Antitussiva und Expektorantien.
Pharm. Unserer Zeit 2008, 37, 462-471; Erratum 2009, 38, 11.

D. Marcinello, S. Ferré, V. Casado, A. Cortés, B. Le Foll, C. Mazzola, F. Drago, O. Saur, H. Stark, A. Soriano, C. Barnes, S. R. Goldberg, C. Lluis, K. Fuxe, and R. Franco.
Identification of Dopamine D1-D3 Receptor Heteromers: Indications for a Role of Synergistic D1-D3 Receptor Interactions in the Striatum.
J. Biol. Chem. 2008, 283, 26016-26025.

M. Jean, J. Renault, J.-C. Camelin, N. Levoin, D. Danvy, H. Stark, M. Capet, and P. Uriac.
A Solid Phase Parallel Synthesis of Diverse Amides as Dopamine D3 Receptor Ligands.
J. Enzym. Inhib. Med. Chem. 2008, 23, 588-592.

2007

X. Ligneau, D. Perrin, L. Landais, J.-C. Camelin, T. P. G. Calmels, I. Berrebi-Bertrand, J.-M. Lecomte, R. Parmentier, C. Anaclet, J.-S. Lin, V. Bertaina-Anglade, C. Drieu la Rochelle, F. d´Aniello, A. Rouleau, F. Gbahou, J.-M. Arrang, C. R. Ganellin, H. Stark, W. Schunack, and J.-C. Schwartz.
BF2.649, a Non-Imidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology.
J. Pharmacol. Exp. Ther. 2007, 320, 365-375.

H. Kubas und H. Stark.
Klassische Wirkstoffentwicklung: Medizinische Chemie von Histamin-H2-Rezeptorantagonisten.
Pharm. unserer Zeit 2007, 36, 24-32.

B. C. Sasse, U. R. Mach, J. Leppaenen, T. Calmels, and H. Stark.
Hybrid Approach for the Design of Highly Affine and Selective Dopamine D3 Receptor Ligands using Privileged Scaffolds of Biogenic Amine GPCR Ligands.
Bioorg. Med. Chem. 2007, 15, 7258-7273.

M. Amon, X. Ligneau, J.-C. Camelin, I. Berrebi-Bertrand, J.-C. Schwartz, and H. Stark.
Highly Potent Fluorescence-Tagged Nonimidazole Histamine H3 Receptor Ligands.
ChemMedChem 2007, 2, 708-716.

O. Saur, A. E. Hackling, S. Perachon, J.-C. Schwartz, P. Sokoloff, and H. Stark.
N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl)cinnamoyl Amide Derivatives as Dopamine D2 and D3 Receptor Ligands.
Arch. Pharm. Chem. Life Sci. 2007, 340, 178-184.

D. Dijkstra, R. Leurs, P. Chazot, F. Shenton, H. Stark, T. Werfel, and R. Gutzmer.
Histamine Down-Regulates Monocyte CCL2 Production via the Histamine H4 Receptor.
J. Allergy Clin. Immunol. 2007, 120, 300-307.

B. Schlegel, C. Laggner, T. Langer, D. Schnell, R. Seifert, H. Stark, H.-D. Höltje, and W. Sippl.
Generation of a Homology Model of the Human Histamine H3 Receptor for Ligand Docking and Pharmacophore-based Screening.
J. Comput. Aided Mol. Des. 2007, 21, 437-453.

A. Böcker, B. C. Sasse, M. Nietert, H. Stark, and G. Schneider.
GPCR Targeted Library Design: Novel Dopamine D3 Receptor Antagonists.
ChemMedChem 2007, 2. 1000-1005.

K. Isensee, G. Petroianu, and H. Stark.
Pharmacological Aspects of Cognitive Impairment: Past, Present, and Future of Drugs in Dementia.
J. Appl. Biosci. 2007, 5, 57-70.

2006

G. Petrianou, K. Arafat, B. C. Sasse and H. Stark
Multiple Enzyme Inhibitions of Histamine H3 Receptor Antagonists as Potential Procognitive Agents.
Pharmazie 2006, 61, 179-182.

D. Łażewska, X. Ligneau, J.-C. Schwartz, W. Schunack, H. Stark and K. Kieć-Kononowicz.
Ether Derivatives of 3-Piperidinopropan-1-ol as Non-Imidazole Histamine H3 Receptor Antagonists.
Bioorg. Med. Chem. 2006, 14, 3522-3529.

M. Amon, X. Ligneau, J.-C. Schwartz and H. Stark
Fluorescent Non-imidazole Histamine H3 Receptor Ligands with Nanomolar Affinities.
Bioorg. Med. Chem. Lett. 2006, 16, 1938-1940.

T. Noeske, B. C. Sasse, H. Stark, C. G. Parsons, T. Weil and G. Schneider
Predicting Compound Selectivity by Self-Organizing Maps: Cross-Activities of Metabotropic Glutamate Receptor Antagonists.
ChemMedChem 2006, 1,1066-1068.

 

2005

B. Le Foll, P. Sokoloff, H. Stark and S. R. Goldberg

Dopamine D3 Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences Through a Mechanism that Does Not Involve Discriminative-Stimulus or Antidepressant-Like Effects.

Neuropsychopharmacology 2005, 30, 720-730.

J. Apelt, S. Graßmann, X. Ligneau, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, W. Schunack and H. Stark

Search for Histamine H3 Receptor Antagonists with Combined Inhibitory Potency at N-Methyltransferase: Ether Derivatives.

Pharmazie 2005, 60, 97-106.

A. Lozada, M. Maegele, H. Stark, E. M. Neugebauer and P. Panula

Traumatic Brain Injury Results in Mast Cell Increase and Changes in Regulation of Central Histamine Receptors.

Neuropathol. Appl. Neurobiol. 2005, 31, 150-162.

B. Schlegel, W. Sippl, H. Stark and H.-D. Höltje

Model of a Specific hH3-Receptor Binding Pocket Suitable for Virtual Drug Design.

Inflamm. Res. 2005, 54 (Suppl. 1), S50-S51.

P. Heidler, V. Zohrabi-Kalantari, M. Capet, T. Calmels, J.-C. Schwartz, H. Stark and A. Link

Parallel Synthesis and Dopamine D2/3 Receptor Affinities of N-{4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl}carboxamides.

Bioorg. Med. Chem. 2005, 13, 2009-2014.

D. Łażewska, K. Kieć-Kononowicz, S. Elz, H. H. Pertz, H. Stark and W. Schunack

Piperidine-Containing Histamine H3 Receptor Antagonists of the Carbamate Class: The Alkyl Derivatives.

Pharmazie 2005, 60, 403-410.

E. Byvatov, B. C. Sasse, H. Stark and G. Schneider

From Virtual to Real Screening for Dopamine D3 Receptor Ligands.

ChemBioChem 2005, 6, 997-999.

C. Guigoni, I. Aubert, Q. Li, V. V. Gurech, J. L. Benovic, S. Ferry, U. Mach, H. Stark. L. Leriche, K. Hakansson, B. H. Bioulac, C. E. Gross, P. Sokoloff, G. Fisone, E. V. Gurevich, B. Bloch and E. Bezard

Pathogenesis of Levodopa-Induced Dyskinesia: Focus on D1 and D3 Dopamine Receptors.

Parkinsonism Rel. Disord. 2005, 11 (Suppl. 1), S25-S29.

R. Gutzmer, C. Diestel, S. Mommert, B. Köther, H. Stark, M. Wittmann and T. Werfel

Histamine H4 Receptor Stimulation Suppress IL-12p70 Production and Mediates Chemotaxis in Human Monocyte-Derived Dendritic Cells.

J. Immunol. 2005, 174, 5224-5232.

M. Schubert-Zsilavecz und H. Stark

Strukturen, Mechanismen und Entwicklungen: Protonenpumpeninhibitoren.

[Proton Pump Inhibitors.]

Pharm. unserer Zeit 2005, 34, 194-199.

H. Stark, Y. Syha, L. Popescu und M. Schubert-Zsilavecz

Innovationen in der Pipeline: Neue Wirkstoffe zur GERD-Behandlung.

[New Drugs for GERD Treatment.]

Pharm. unsere Zeit 2005, 34, 224-227.

H. Stark und M. Schubert-Zsilavecz

Medizinische Chemie der L-Typ-Calcium-Kanalblocker.

[The Medicinal Chemistry of L-Type Calcium Channel Blockers.]

Pharm. unserer Zeit 2005, 34, 374-379.

2004

U. R. Mach, A. E. Hackling, S. Perachon, S. Ferry, C. G. Wermuth, J.-C. Schwartz, P. Sokoloff and H. Stark
Development of Novel 1,2,3,4-Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands.
ChemBioChem 2004, 5, 508-518.

H. Stark und M. Schubert-Zsilavecz
Entwicklungen, Strukturen und neue Tendenzen: H1-Antihistaminika.
[Development, Structures and New Trends: H1-Antihistamines.]
Pharm. unserer Zeit 2004, 33 (2), 92-98.

O. Guillin, N. Griffon, J. Diaz, B. LeFoll, E. Bezard, C. Gross, C. Lammers, H. Stark, P. Carroll, J.-C. Schwartz and P. Sokoloff
Brain-Derived Neurotrophic Factor and the Plasticity of the Mesolimbic Dopamine Pathway.
Int. Rev. Neurobiol. 2004, 59, 425-444.

T. Mikó, X. Ligneau, H. H. Pertz, J.-M. Arrang, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
Structural Variations of 1-(4-(Phenoxymethyl)benzyl)piperidines as Nonimidazole Histamine H3 Receptor Antagonists.
Bioorg. Med. Chem. 2004, 12, 2727-2783.

G. Meier, M. Krause, A. Hüls, X. Ligneau, H. H. Pertz, J.-M. Arrang, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
4-(w-(Alkyloxy)alkyl)-1H-imidazole Derivatives as Histamine H3 Receptor Antagonists / Agonists.
J. Med. Chem. 2004, 47, 2678-2687.

N. Pelloux-Léon, A. Fkyerat, A. Piripitsi, W. Tertiuk, W. Schunack, H. Stark, M. Garbarg, X. Ligneau, J.-M. Arrang, J.-C. Schwartz and C. R. Ganellin
Meta-Substituted Aryl(thio)ethers as Potent Partial Agonists (or Antagonists) for the Histamine H3 Receptor Lacking a Nitrogen Atom in the Side Chain.
J. Med. Chem. 2004, 47, 3264-3274.

M. Schubert-Zsilavecz und H. Stark
Wiederaufnahme-Hemmung an der Präsynapse als Wirkprinzip:
Medizinische Chemie moderner Antidepressiva – Targets und Arzneistoffe.
[Resumption-Inhibition in Presynaptic Action: The Medicinal Chemistry of Modern Antidepressants.]
Pharm. unsere Zeit 2004, 33, 282-287.

H. Stark, M. Kathmann, E. Schlicker, W. Schunack, B. Schlegel and W. Sippl
Medicinal Chemical and Pharmacological Aspects of Imidazole-Containing Histamine H3 Receptor Antagonists.
Mini Rev. Curr. Med. Chem. 2004, 4, 965-977.

S. Graßmann, J. Apelt, X. Ligneau, H. H. Pertz, J.-M. Arrang, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
Search for Histamine H3 Receptor Antagonists with Combined Inhibitory Potency at N-Methyltransferase: w-Piperidinoalkanamine Derivatives.
Arch. Pharm. Pharm. Med. Chem. 2004, 337, 533-545.

A. Lozada, A. A. Aarnisalo, K. Karlstedt, H. Stark and P. Panula
Plasticity of Histamine H3 Receptor Expression and Binding in the Vestibular Nuclei after Labyrinthectomy in Rat.
BMC Neuroscience 2004, 5, 32.
doi:10.1186/1471-2202-5-32; www.biomedcentral.com/1471-2202/5/32

B. Sadek, S. Elz, H. H. Pertz, H. Stark and W. Schunack
Unexpected Partial H1-Receptor Agonism of Imidazole-Type Histamine H3-Receptor Antagonists Lacking a Basic Side-Chain.
Inflamm. Res. 2004, 53 (Suppl. 2), S109-S115.

P. P. Griffin, M. Schubert-Zsilavecz and H. Stark
Hemmstoffe von ß-Adrenozeptoren: Gemeinsamkeiten und Unterschiede.
[Common Properties and Distinctions: Inhibitors of ß-Adrenoceptors.]
Pharm. unserer Zeit 2004, 33, 442-449.

H. Stark
Turning from Monogamy to Strategic Promiscuity.
Drug Discov. Today 2004, 9, 736-737.

2003

S. Liedtke, K. Flau, M. Kathmann, E. Schlicker, H. Stark, G. Meier and W. Schunack
Replacement of Imidazole by a Piperidine Moiety Differentially Affects the Potency of Histamine H3-Receptor Antagonists.
Naunyn-Schmiedeberg´s Arch. Pharmacol. 2003, 367, 43-50.

E. Bézard, S. Ferry, U. Mach, H. Stark, L. Leriche, T. Boraud, C. Gross and P. Sokoloff
Attenuation of Levodopa-Induced Dyskinesia by Normalizing Dopamine D3 Receptor Function.
Nat. Med. 2003, 9(6), 762-767.

T. Mikó, X. Ligneau, H. H. Pertz, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, W. Schunack and H. Stark
Novel Nonimidazole Histamine H3 Receptor Antagonists: 1-(4-(Phenoxymethyl)benzyl)­piperidines and Related Compounds.
J. Med. Chem. 2003, 46, 1523-1530.

S. Graßmann, J. Apelt, W. Sippl, X. Ligneau, H. H. Pertz, Y. H. Zhao, J.-M. Arrang, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
Imidazole Derivatives as a Novel Class of Hybrid Compounds with Inhibitory Histamine N-Methyltransferase Potencies and Histamine hH3 Receptor Affinities.
Bioorg. Med. Chem. 2003, 11(10), 2163-2174.

A. Hackling, R. Ghosh, S. Perachon, A. Mann, H.-D. Höltje, C. G. Wermuth, J.-C. Schwartz, W. Sippl, P. Sokoloff and H. Stark
N-(w-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands.
J. Med. Chem. 2003, 46, 3883-3899.

H. Stark
Recent Advances in Histamine H3/H4 Receptor Ligands.
Expert Opin. Ther. Patents 2003, 13(6), 851-865 (Review).

J.-C. Schwartz, S. Morisset, A. Rouleau, X. Ligneau, F. Gbahou, J. Tardivel-Lacombe, H. Stark, W. Schunack, C. R. Ganellin and J.-M. Arrang
Therapeutic Implications of Constitutive Activity of Receptors: The Example of the Histamine H3Receptor.
J. Neural Transm. 2003, 64 Suppl., 1-16.

F. Gbahou, A. Rouleau, S. Morisset, R. Parmentier, S. Crochet, J.-S. Lin, X. Ligneau, J. Tardivel-Lacombe, H. Stark, W. Schunack, C. R. Ganellin, J.-C. Schwartz and J.-M. Arrang
Protean Agonism at Histamine H3 Receptors in Vitro and in Vivo.
Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11086-11091.

H. Stark
Wirkmechanismus von HMG-CoA-Reduktase-Inhibitoren – Medizinisch-chemische Aspekte von Statinen.
[Mechanism of Action of HMG-CoA Reductase Inhibitors. Medical-Chemical Aspects of Statins.]
Pharm. unserer Zeit 2003, 32 (6), 464-470.

2002

M. Więcek, K. Kieć-Kononowicz, A. Sasse, X. Ligneau, J.-C. Schwartz, W. Schunack and H. Stark
Impact of Lipophilicity on the Pharmacological Properties of Histamine H3-Receptor Antagonists of the Cycloalkyl Carbamate Class.
Inflamm. Res. 2002, 51 (Suppl. 1), S71–S72.

G. Meier, X. Ligneau, H. Pertz, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
Piperidino-Hydrocarbon Compounds as Novel Non-Imidazole Histamine H3-Receptor Antagonists.
Bioorg. Med. Chem. 2002, 10, 2535–2542.

J. Apelt, X. Ligneau, H. H. Pertz, J.-M. Arrang, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
Development of a New Class of Nonimidazole Histamine H3 Receptor Antagonist with Combined Inhibitory Histamine N-Methyltransferase Activity.
J. Med. Chem. 2002, 45, 1128–1141.

S. Graßmann, B. Sadek, X. Ligneau, S. Elz, C. R. Ganellin, J.-C. Schwartz, H. Stark and W. Schunack
Progress in the Proxifan Class: Heterocyclic Congeners as Novel Potent and Selective Histamine H3-Receptor Antagonists.
Eur. J. Pharm. Sci. 2002, 15, 367–378.

A. Sasse, X. Ligneau, A. Rouleau, S. Elz, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, W. Schunack and H. Stark
Influence of Bulky Substituents on Histamine H3 Receptor Agonist/Antagonist Properties.
J. Med. Chem. 2002, 45, 4000–4010.

D. Łażewska, K. Kieć-Kononowicz, H. H. Pertz, H. Stark and W. Schunack
Piperidine-Containing Histamine H3-Receptor Antagonists of the Carbamate Series: The Influence of the Additional Ether Functionality.
Pharmazie 2002, 57(12), 791-795.

A. E. Hackling and H. Stark
Dopamine D3 Receptor Ligands with Antagonist Properties.
ChemBioChem 2002, 3, 946-961 (Review).

2001

H. Stark, M. Krause, A. Rouleau, M. Garbarg, J.-C. Schwartz and W. Schunack
Enzyme-Catalyzed Prodrug Approaches for the Histamine H3-Receptor Agonist (R)-a-Methylhistamine.
Bioorg. Med. Chem. 2001, 9, 191-198.

A. Sasse, W. Schunack and H. Stark
Separation of Chiral 4-Substituted Imidazole Derivatives by Cyclodextrin-Modified Capillary Electrophoresis.
Biomed. Chromatogr. 2001, 15, 25-30.

A. Sasse, X. Ligneau, B. Sadek, S. Elz, H. H. Pertz, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, W. Schunack and H. Stark
Benzophenone Derivatives and Related Compounds as Potent Histamine H3-Receptor Antagonists and Potential PET/SPECT Ligands.
Arch. Pharm. Pharm. Med. Chem. 2001, 334, 45-52.

G. Meier, J. Apelt, U. Reichert, S. Graßmann, X. Ligneau, S. Elz, F. Leurquin, C. R. Ganellin, J.-C. Schwartz, W. Schunack and H. Stark
Influence of Imidazole Replacement in Different Structural Classes of Histamine H3-Receptor Antagonists.
Eur. J. Pharm. Sci. 2001, 13, 249-259.

H. Stark, W. Sippl, X. Ligneau, J.-M. Arrang, C. R. Ganellin, J.-C. Schwartz and W. Schunack
Different Antagonist Binding Properties of Human and Rat Histamine H3 Receptors.
Bioorg. Med. Chem. Lett. 2001, 11, 951-954.

T. Nickel, U. Bauer, E. Schlicker, M. Kathmann, M. Göthert, A. Sasse, H. Stark and W. Schunack
Novel Histamine H3-Receptor Antagonists and Partial Agonists with a Non-Aminergic Structure.
Br. J. Pharmacol. 2001, 132, 1665-1672.

G. Morini, D. Grandi, A. Sasse, H. Stark and W. Schunack
Gastroprotective Acitivity of the Novel Histamine H3-Receptor Agonist FUB 407.
Inflamm. Res. 2001, 50 (Suppl. 2), S116-S117.

M. Krause, H. Stark and W. Schunack
Azomethine Prodrugs of (R)-a-Methylhistamine, a Highly Potent and Selective Histamine H3-Receptor Agonist.
Curr. Med. Chem.2001, 8, 1329-1340 (Review).

B. Weber, E. Schlicker, P. Sokoloff and H. Stark
Identification of the Dopamine Autoreceptor in the Guinea-Pig Retina as D2 Receptor Using Novel Subtype-Selective Antagonists.
Br. J. Pharmacol. 2001, 133, 1243-1248.

J.-C. Schwartz, S. Morisset, A. Rouleau, J. Tardivel-Lacombe, F. Gbahou, X. Ligneau, A. Heron, A. Sasse, H. Stark, W. Schunack, C. R. Ganellin and J.-M. Arrang
Application of Genomics to Drug Design: The Example of the Histamine H3 Receptor.
Eur. Neuropsychopharmacol. 2001, 11, 441-448.

D. Lazewska, K. Kieć-Kononowicz, H. H. Pertz, H. Stark, W. Schunack and S. Elz
Piperidine-Containing Histamine H3-Receptor Antagonists of the Carbamate Series: Variation of the Spacer Length.
Pharmazie 2001, 56, 927-932.

2000

S. Reidemeister, H. Stark, X. Ligneau, C. R. Ganellin, J.-C. Schwartz and W. Schunack

Substituted N-Phenyl Carbamates as Histamine H3 Receptor Antagonists with Improved in Vivo Potency.
Pharmazie 2000, 55, 83-86.

K. Kieć-Kononowicz, M. Więcek, A. Sasse, X. Ligneau, S. Elz, C. R. Ganellin, J.-C. Schwartz, H. Stark and W. Schunack
Importance of the Lipophilic Group in Carbamates Having Histamine H3-Receptor Antagonist Activity.
Pharmazie 2000, 55, 349-355.

G. Morini, D. Grandi, H. Stark and W. Schunack
Histamine H3-Receptor Antagonists Inhibit Gastroprotection by (R)-a-Methylhistamine in the Rat.
Br. J. Pharmacol. 2000, 129, 1597-1600.

A. Sasse, H. Stark, X. Ligneau, S. Elz, S. Reidemeister, C. R. Ganellin, J.-C. Schwartz and W. Schunack
(Partial) Agonist/Antagonist Properties of Novel Diarylalkyl Carbamates on Histamine H3 Receptors.
Bioorg. Med. Chem. 2000, 8, 1139-1149.

H. Stark, S. Graßmann und U. Reichert
Struktur, Funktion und potentielle therapeutische Bedeutung von NMDA-Rezeptoren.
Teil 1: Architektur und Modulation der Rezeptoren.
[Structure, Function and Potential Therapeutic Possibilites of NMDA Receptors.
1. Architecture and Modulation of Receptors.]
Pharm. unserer Zeit 2000, 29, 159-166 (Review).
 

H. Stark, U. Reichert und S. Graßmann
Struktur, Funktion und potentielle therapeutische Bedeutung von NMDA-Rezeptoren.
Teil 2: Therapiekonzepte und neue Rezeptorliganden.
[Structure, Function and Potential Therapeutic Possibilities of NMDA Receptors.
2. Therapy Concepts and New Receptor Ligands.]
Pharm. unserer Zeit 2000, 29, 228-236 (Review).

A. Sasse, B. Sadek, X. Ligneau, S. Elz, H. H. Pertz, P. Luger, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, W. Schunack and H. Stark
New Histamine H3-Receptor Ligands of the Proxifan Series: Imoproxifan and Other Selective Antagonists with High Oral in Vivo Potency.
J. Med. Chem. 2000, 43, 3335-3343.

A. Rouleau, H. Stark, W. Schunack and J.-C. Schwartz
Anti-Inflammatory and Antinociceptive Properties of BP 2-94, a Histamine H3-Receptor Agonist Prodrug.
J. Pharmacol. Exp. Ther. 2000, 295, 219-225.

H. Stark, X. Ligneau, B. Sadek, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz and W. Schunack
Analogues and Derivatives of Ciproxifan, a Novel Prototype for Generating Potent Histamine H3-Receptor Antagonists.
Bioorg. Med. Chem. Lett.2000, 10, 2379-2382.

H. Stark, B. Sadek, M. Krause, A. Hüls, X. Ligneau, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz and W. Schunack
Novel Histamine H3-Receptor Antagonists with Carbonyl-Substituted 4-(3-(Phenoxy)propyl)-1H-imidazole Structures like Ciproxifan and Related Compounds.
J. Med. Chem. 2000, 43, 3987-3994.

S. Morisset, A. Rouleau, X. Ligneau, F. Gbahou, J. Tardivel-Lacombe, H. Stark, W. Schunack, C. R. Ganellin, J.-C. Schwartz and J.-M. Arrang
High Constitutive Activity of Native H3 Receptor Regulates Histamine Neurones in Brain.
Nature (London) 2000, 408, 860-864.

X. Ligneau, S. Morisset, J. Tardivel-Lacombe, F. Gbahou, C. R. Ganellin, H. Stark, W. Schunack, J.-C. Schwartz and J.-M. Arrang
Distinct Pharmacology of Rat and Human Histamine H3 Receptors: Role of Two Amino Acids in the Third Transmembrane Domain.
Br. J. Pharmacol. 2000, 131, 1247-1250 (Special Report).

H. Stark
Convenient Procedures for Synthesis of Ciproxifan, a Histamine H3-Receptor Antagonist.
Arch. Pharm. Pharm. Med. Chem. 2000, 333, 315-316.

1999

A. Sasse, K. Kieć-Kononowicz, H. Stark, M. Motyl, S. Reidemeister, C. R. Ganellin, X. Ligneau, J.-C. Schwartz and W. Schunack
Development of Chiral N-Alkyl Carbamates as New Leads for Potent and Selective H3-Receptor Antagonists: Synthesis, Capillary Electrophoresis, and in Vitro and Oral in Vivo Activity.
J. Med. Chem. 1999, 42, 593-600.

N. Matzanke, W. Löwe, S. Perachon, P. Sokoloff, J.-C. Schwartz and H. Stark
Heterocyclic Congeners of PD 128,907 with a Partially Hydrogenated Benzomorpholine Moiety as Potential Dopamine D3-Receptor Ligands.
Eur. J. Med. Chem. 1999, 34, 791-798.

A. D. Windhorst, H. Timmerman, R. P. Klok, F. G. J. Custers, W. M. P. B. Menge, R. Leurs, H. Stark, W. Schunack, E. G. J. Gielen, M. J. P. G.    van Kroonen­burgh and J. D. M. Herscheid
Radiosynthesis and Biodistribution of 123I-Labeled Antagonists of the Histamine H3 Receptor as Potential SPECT Ligands.
Nucl. Med. Biol. 1999, 26, 651-659.

A. Sasse, H. Stark, S. Reidemeister, A. Hüls, S. Elz, X. Ligneau, C. R. Ganellin, J.-C. Schwartz and W. Schunack
Novel Partial Agonists for the Histamine H3 Receptor with High in Vitro and in Vivo Activity.
J. Med. Chem. 1999, 42, 4269-4274.

A. D. Windhorst, H. Timmerman, R. P. Klok, F. G. J. Custers, W. M. P. B. Menge, R. Leurs, H. Stark, W. Schunack, M. J. P. G. van Kroonenburgh and J. D. M. Herscheid
Radiosynthesis and Biodistribution of 123I Labeled Antagonists as Potential SPECT Ligands for the Histamine H3 Receptor.
J. Labell. Compd. Radiopharm. 1999, 42 (Suppl. 1), S282-S284

1998

H. Stark, A. Hüls, X. Ligneau, K. Purand, H. Pertz, J.-M. Arrang, J.-C. Schwartz and W. Schunack
Development of FUB 181, a Selective Histamine H3-Receptor Antagonist of High Oral in Vivo Potency with         4-(w-(Arylalkyloxy)alkyl)-1H-imidazole Structure.
Arch. Pharm. Pharm. Med. Chem. 1998, 331, 211-218.

K. Onodera, S. Miyazaki, M. Imaizumi, H. Stark and W. Schunack
Improvement by FUB 181, a Novel Histamine H3-Receptor Antagonist, of Learning and Memory in the Elevated Plus-Maze Test in Mice.
Naunyn-Schmiedeberg´s Arch. Pharmacol. 1998, 357, 508-513.

W. Sippl, H. Stark and H.-D. Höltje
Development of a Binding Site Model for Histamine H3-Receptor Agonists.
Pharmazie 1998, 53, 433-437.

X. Ligneau, J.-S. Lin, G. Vanni-Mercier, M. Jouvet, J. L. Muir, C. R. Ganellin, H. Stark, S. Elz, W. Schunack and J.-C. Schwartz
Neurochemical and Behavioral Effects of Ciproxifan, a Potent Histamine H3-Receptor Antagonist.      
J. Pharmacol. Exp. Ther. 1998, 287, 658-666.

A. Lecklin, P. Etu-Seppälä, H. Stark and L. Tuomisto
Effects of Intracerebroventricular Infused Histamine and Selective H1, H2 and H3 Agonists on Food and Water Intake and Urine Flow in Wistar Rats.
Brain Res. 1998, 793, 279-288.

H. Stark, X. Ligneau, J.-M. Arrang, J.-C. Schwartz and W. Schunack
General Construction Pattern of Histamine H3-Receptor Antagonists: Change of a Paradigm.
Bioorg. Med. Chem. Lett. 1998, 8, 2011-2016.

M. Krause, X. Ligneau, H. Stark, M. Garbarg, J.-C. Schwartz and W. Schunack
4-Alkynylphenyl Imidazolpropyl Ethers as Selective Histamine H3-Receptor Antagonists with High Oral Central Nervous System Activity.
J. Med. Chem. 1998, 41, 4171-4176.

M. Kathmann, E. Schlicker, I. Marr, S. Werthwein, H. Stark and W. Schunack
Ciproxifan and Chemically Related Compounds are Highly Potent and Selective Histamine H3-Receptor Antagonists.
Naunyn-Schmiedeberg´s Arch. Pharmacol. 1998, 358, 623-627.

1997

H. Stark, X. Ligneau, R. Lipp, J.-M. Arrang, M. Garbarg, J.-C. Schwartz and W. Schunack
Search for Novel Leads for Histamine H3-Receptor Antagonists: Amine Derivatives.
Pharmazie 1997, 52, 419-423.

A. Rouleau, M. Garbarg, X. Ligneau, C. Mantion, P. Lavie, C. Advenier, J.-M. Lecomte, M. Krause, H. Stark, W. Schunack and J.-C. Schwartz
Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, an Histamine H3 Receptor Agonist Prodrug.
J. Pharmacol. Exp. Ther. 1997, 281, 1085-1094.

H. Stark, A. Hüls, X. Ligneau, J.-M. Arrang, J.-C. Schwartz and W. Schunack
Search for Novel Leads for Histamine H3-Receptor Antagonists: Oxygen-containing Derivatives,
Pharmazie 1997, 52, 495-500.

S. Corbel, E. Traiffort, H. Stark, W. Schunack and M. Dy
Binding of Histamine H3-Receptor Antagonists to Hematopoietic Progenitor Cells: Evidence for a Histamine Transporter Unrelated to Histamine H3 Receptors.
FEBS Lett. 1997, 404, 289-293.

M. Krause, H. Stark and W. Schunack
Iododestannylation: An Improved Synthesis of [125I]Iodoproxyfan, a Specific Radioligand of the Histamine H3-Receptor.
J. Labell. Compd. Radiopharm. 1997, 39, 601-606.

1996

H. Stark, K. Purand, X. Ligneau, A. Rouleau, J.-M. Arrang, M. Garbarg, J.-C. Schwartz and W. Schunack
Novel Carbamates as Potent Histamine H3 Receptor Antagonists with High in Vitro and Oral in Vivo Activity.
J. Med. Chem. 1996, 39, 1157-1163.

H. Stark, K. Purand, A. Hüls, X. Ligneau, M. Garbarg, J.-C. Schwartz and W. Schunack
[125I]Iodoproxyfan and Related Compounds: A Reversible Radioligand and Novel Classes of Antagonists with High Affinity and Selectivity for the Histamine H3 Receptor.
J. Med. Chem. 1996, 39, 1220-1226.

E. Schlicker, M. Kathmann, H. Bitschnau, I. Marr, S. Reidemeister, H. Stark and W. Schunack
Potencies of Antagonists Chemically Related to Iodoproxyfan at Histamine H3 Receptors in Mouse Brain Cortex and Guinea-pig Ileum: Evidence for H3 Receptor Heterogeneity?
Naunyn-Schmiedeberg´s Arch. Pharmacol. 1996, 353, 482-488.

M. Krause, A. Rouleau, H. Stark, P. Luger, M. Garbarg, J.-C. Schwartz and W. Schunack
New Potent Azomethine Prodrugs of the Histamine H3-Receptor Agonist (R)-a-Methylhistamine Containing a Heteroarylphenyl Partial Structure.
Arch. Pharm. Pharm. Med. Chem. 1996, 329, 209-215.

H. Stark, E. Schlicker and W. Schunack
Developments of Histamine H3-Receptor Antagonists.
Drugs Future 1996, 21, 507-520 (Review).

A. Hüls, K. Purand, H. Stark, S. Reidemeister, X. Ligneau, M. Garbarg, J.-C. Schwartz and W. Schunack
Novel Histamine H3-Receptor Antagonists with Benzyl Structure or Related Moieties: Synthesis and Structure-Activity Relationships.
Arch. Pharm. Pharm. Med. Chem. 1996, 329, 379-385.

A. Hüls, K. Purand, H. Stark, X. Ligneau, J.-M. Arrang, J.-C. Schwartz and W. Schunack
Diphenylmethy Ethers: Synthesis and Histamine H3-Receptor Antagonist in Vitro and in Vivo Activity.
Bioorg. Med. Chem. Lett. 1996, 6, 2013-2018.

M. Krause, A. Rouleau, H. Stark, M. Garbarg, J.-C. Schwartz and W. Schunack
Structure-Activity Relationships of Novel Azomethine Prodrugs of the Histamine H3-Receptor Agonist (R)-a-Methylhistamine: From Alkylaryl to Substituted Diaryl Derivatives.
Pharmazie 1996, 51, 720-726.

M. Krause, A. Rouleau, H. Stark, M. Garbarg, J.-C. Schwartz and W. Schunack
Relationship between Lipophilicity and Brain Uptake of Azomethine Prodrugs of a Histamine H3-Receptor Agonist.
Sci. Pharm. 1996, 64, 503-509.

1995

R. Lipp, H. Stark, J. M. Arrang, M. Garbarg, J. C. Schwartz and W. Schunack
Synthesis and Histamine H3-Receptor Agonist Activity of Mono- and Dialkyl-Substituted Histamine Derivatives.
Eur. J. Med. Chem. 1995, 30, 219-225.

H. Stark, R. Lipp, J.-M. Arrang, M. Garbarg, X. Ligneau, J.-C. Schwartz and W. Schunack
New Potent Histamine H3-Receptor Antagonists of the Amide Type
Eur. J. Pharm. Sci. 1995, 3, 95-104.

W. Sippl, H. Stark and H. D. Höltje
Computer-Assisted Analysis of Histamine H2- and H3-Receptor Agonists.
Quant. Struct.-Act. Relation. 1995, 14, 121-125.

K. Kieć-Kononowicz, X. Ligneau, H. Stark, J.-C. Schwartz and W. Schunack
Azines and Diazines as Potential Histamine H3-Receptor Antagonists.
Arch. Pharm. (Weinheim) 1995, 328, 445-450.

M. Krause, A. Rouleau, H. Stark, P. Luger, R. Lipp, M. Garbarg, J.-C. Schwartz and W. Schunack
Synthesis, X-ray Crystallography, and Pharmacokinetics of Novel Azomethine Prodrugs of (R)-a-Methylhistamine: Highly Potent and Selective Histamine H3 Receptor Agonists.
J. Med. Chem. 1995, 38, 4070-4079.

1994

E. Schlicker, M. Kathmann, S. Reidemeister, H. Stark and W. Schunack
Novel Histamine H3 Receptor Antagonists: Affinities in an H3 Receptor Binding Assay and Potencies in Two Functional HReceptor Models.
Br. J. Pharmacol. 1994, 112, 1043-1048; ibid. 1994, 113, 637.

H. Stark, R. Lipp, J.-M. Arrang, M. Garbarg, J.-C. Schwartz and W. Schunack
Acylated and Alkylated Histamine Derivatives as New Histamine H3-Receptor Antagonists.
Eur. J. Med. Chem. 1994, 29, 695-700.

W. Schunack and H. Stark
Design of Histamine H3-Receptor Agonists and Antagonists.
Eur. J. Drug Metab. Pharmacokin. 1994, 19, 173-178 (Review).

X. Ligneau, M. Garbarg, M. L. Vizuete, J. Diaz, K. Purand, H. Stark, W. Schunack and J.-C. Schwartz
[125I]Iodoproxyfan, a New Antagonist to Label and Visualize Cerebral Histamine H3 Receptors.
J. Pharmacol. Exp. Ther. 1994, 271, 452-459.

H. Stark, M. Krause, J.-M. Arrang, X. Ligneau, J.-C. Schwartz and W. Schunack
Unsymmetrically Substituted Guanidines as Potent Histamine H3-Receptor Antagonists.
Bioorg. Med. Chem. Lett. 1994, 4, 2907-2912.

1991

E. Poli, H. Stark and G. Bertaccini
Histamine H3-Receptor Activation Inhibits Acetylcholine Release from the Guinea Pig Myenteric Plexus.
Agents Actions 1991, 33, 167-169.

H. Stark
Zur Arzneistoffentwicklung von Prodrugs mit agonistischer Wirkform und Antagonisten des Histamin-H3-Rezeptors.
Dissertation, Freie Universität Berlin, Berlin, Germany, 1991.

 

C. R. Ganellin, J.-C. Schwartz and H. Stark.
Discovery of Pitolisant, the First Marketed Histamine H3-Receptor Inverse Agonist/Antagonist for Treating Narcolepsy.
Successful Drug Discovery, Vol. 3 (Eds. J. Fischer, C. Klein, W. E. Childers), Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim, Germany, 2018, pp. 359-381.
Online ISBN:9783527808694; DOI:10.1002/9783527808694.

G. Alpert und H. Stark.
3.8 Peptische Ulzera.
Pharmakogenetik und Therapeutisches Drug Monitoring (Hrsg. H.-G. Klein, E. Haen), Walter De Gruyter Verlag, Berlin/Boston, 2018, pp. 313-331.
ISBN: 978-3-11-035286-3 / e-ISBN (PDF): 978-3-11-035290-0 / e-ISBN (EPUB): 978-3-11-038780-3.

L. Stank und H. Stark.
3.12 Morbus Parkinson.
Pharmakogenetik und Therapeutisches Drug Monitoring (Hrsg. H.-G. Klein, E. Haen), Walter De Gruyter Verlag, Berlin/Boston, 2018, pp. 379-398.
ISBN: 978-3-11-035286-3 / e-ISBN (PDF): 978-3-11-035290-0 / e-ISBN (EPUB): 978-3-11-038780-3.

H. Stark.
6. Pharmakologie des Histamins.
Allgemeine und spezielle Pharmakologie und Toxikologie. (Hrsgb. K. Aktories, U. Förstermann, F. Hofmann, K. Starke), 12. Auflage, 2017, Elsevier-Urban & Fischer, München, pp. 181-188.
ISBN 978-3-437-42525-7; eISBN 978-3-437-17212-0

B. Sadek, D. Lazewska, S. Kassel, K. Kiec-Kononowicz, and H. Stark.
Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates.
Histamine Receptors – Preclinical and Clinical Aspects (Eds. P. Blandina, M. B. Passani), Humana Press (Ser. Receptors, Vol. 28; Ed. G. di Giovanni) Springer Nature, Cham/Switzerland, 2016, pp. 109-155. DOI 10.1007/978-3-319-40308-3.
ISBN 978-3-319-40306-9; ISBN 978-3-319-40308-3.

H. Stark.
German Pharmacy Education.
実用薬学英語 [Practical Pharmacy English] Japanese textbook – Pharmacy Association of Japan (Ed. Toshio Kaneko) 東京化学同人 [Tokyo Kagakudojin/Japan], 2015, pp. 47-48.
ISBN 978-4-8079-0865-3.

M. Stein and H. Stark (Editors)
I3 – Interactions, Integrations and Innovations – Conference Book, Odenkirchener Druck- und Verlags GmbH, Mönchengladbach,Düsseldorf/Germany, 2015, 226 pages.
ISBN: 978-3-9816225-2-2

H. Stark.
Psychostimulants.
Ullmann´s Encyclopedia of Industrial Chemistry, (Ed. B. Elvers et al.), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim/Germany, 2014, pp. 1 – 5 (a02_267).
Online ISBN: 9783527306732; DOI: 10.1002/14356007;
onlinelibrary.wiley.com/doi/10.1002/14356007.a02_267.pub2/full

H. Stark, (Editor; eBook – open access)
Histamine H4 receptor: A novel drug target for immunoregulation and inflammation. Versita-deGruyter, London/UK, 2013, 368 pages, open access.
ISBN: 978-83-7656-056-4 (for electronic copy); doi: 10.2478/9788376560564,
ISBN: 978-83-7656-054-0 (paperback); ISBN: 978-83-7656-055-7 (hardcover)
www.degruyter.com/viewbooktoc/product/209714

H. Stark.
The Histamine H4 Receptor Story.
In: Histamine H4 receptor: A novel drug target for immunoregulation and inflammation (Ed. Stark, H.), Versita, London/UK, 2013, pp. 15-20 (open access).
ISBN: 978-83-7656-056-4,
www.degruyter.com/view/books/9788376560564/9788376560564.c1/9788376560564.c1.xml

A. Schreeb, S. Dove, D. Lazewska, A. Buschauer, K. Kiec-Knonowiecz, and H. Stark.Histamine H4 Receptor Ligands.
In: Histamine H4 receptor: A novel drug target for immunoregulation and inflammation (Ed. Stark, H.), Versita, London/UK, 2013, pp. 21-61 (open access).
ISBN: 978-83-7656-056-4,
www.degruyter.com/view/books/9788376560564/9788376560564.c2/9788376560564.c2.xml

H. Stark.
Similarities and Differences in Small Molecule Drug Design.
Proceedings of the International Conference (Humboldt-Kolleg) „How Science Spies on and Technology Imitates nature“, Gdansk, September 25-28, 2011, Ed. A. M. Klonkowski, M. Jaskula, Uniwersytetu Gdanskiego/Poland, 2013, pp. 85-92.
ISBN-13: 978-83-7865-052-2.

G. Schneider, H. Stark, und I. Zündorf.
Pharmatett – Giftpflanzen.
Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn, 2012.
(ISBN: 978-3-7741-1193-6).

H. Stark und D. Glass.
Pharmatett – Selbstmedikation.
Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn, 2012.
(ISBN: 978-3-7741-1157-8).

H. Stark.
Pharmatett – Antiinfektiva.
Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn, 2010.
(ISBN 978-3-7741-1120-2).

H. Stark.
Pharmatett – ZNS-Arzneistoffe.
Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn, 2010.
(ISBN 978-3-7741-1122-6).

H. Stark und G. Schneider.
Pharmatett – Allgemeine Arzneistoffe.
Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn, 2010.
(ISBN 978-3-7741-1119-6).

H. Stark und I. Zündorf.
Pharmatett – Arzneipflanzen.
Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn, 2010.
(ISBN 978-3-7741-1121-9).

S. Celanire, F. Lebon, and H. Stark.
Drug Discovery: From Hits to Clinical Candidates.
The Third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CNS Disorders (eds. D. Vohora), CRC Press, Taylor & Francis CRC Press Inc., Boca Raton, Fla/USA., 2009, pp. 103-165.
(ISBN: 9781420053920 - 1420053922).

H. Stark and W. Schunack.
Histamine H3-Receptor Agonists and Antagonists: Chemical, Pharmacological and Clinical Aspects.
Chemistry and Molecular Aspects of Drug Design and Action. (eds. E. A. Rekka and P.N. Kourounakis), CRC Press, Taylor & Francis Group, Boca Raton, Fla/USA., 2008, pp. 199-214 (Chapter 14).
(ISBN: 9780849390067).

S. Müllner, H. Stark, P. Niskanen, E. Eigenbrodt, S. Mazurek, and H. Fasold.
From Target to Lead Synthesis.
Methods and Principles in Medicinal Chemistry (28) (Proteomics in Drug Research; Ed. M. Hamacher, K. Marcus, K. Stühler, A. van Hall, B. Warscheid, and H. E. Meyer), Ed. R. Mannhold, H. Kubinyi, and G. Folkers, Wiley-VCH Verlag GmbH Co.KGaG, Weinheim, Germany, 2006, pp. 187-207.
(ISBN: 3-527-31226-9).

E. Barreiro, A. Fontes Prado, R. Ganellin, C. Wermuth, E. Breuer, A. Buschauer, H. Stark, and A. Monge.
Practical Studies for Medicinal Chemistry Students - An Integrating Approach for Developing Countries.
IUPAC, Online book outline, 2006.
www.iupac.org/projects/2004/2004-028-1-700.html
www.iupac.org/publications/cd/medicinal_chemistry/index.html

J.-M. Arrang, S. Morisset, A. Rouleau, F. Gbahou, X. Ligneau, J. Tardivel-Lecombe, H. Stark, W. Schunack, C. R. Ganellin, and J.-C. Schwartz.
Constitutive Activity of the Recombinant and Native Histamine H3 Receptor.
In: Inverse Agonism - Proceedings of the Esteve Foundation Symposium X (ed. A. P. Ilzerman), International Congress Series, Vol. 1249, Elsevier Science B.V., Amsterdam 2003, pp. 139-151.
(ISSN: 0531-5131).

W. Schunack, A. Sasse, H. Stark, S. Elz, X. Ligneau, C. R. Ganellin, and J.-C. Schwartz.
Partial Agonists for the Histamine H3 Receptor with High in Vivo Activity.
In: Histamine Research in the New Millennium (eds. T. Watanabe, H. Timmerman, and K. Yanai), International Congress Series, Vol. 1224, Elsevier Science B.V., Amsterdam 2001, pp. 77-82.
(ISBN: 0-444-50582-2).

C. R. Ganellin, F. Leurquin, A. Piripitsi, J.-M. Arrang, M. Garbarg, X. Ligneau, H. Stark, W. Schunack, and J.-C. Schwartz.
The Discovery of Potent Non-Imidazole H3-Receptor Histamine Antagonists.
In: Histamine Research in the New Millennium (eds. T. Watanabe, H. Timmerman, and K. Yanai), International Congress Series, Vol. 1224, Elsevier Science B.V., Amsterdam 2001, pp. 25-31.
(ISBN: 0-444-50582-2).

J.-M. Arrang, S. Morisset, A. Rouleau, J. Tardivel-Lacombe, F. Gbahou, X. Ligneau, A. Héron, A. Sasse, H. Stark, W. Schunack, C. R. Ganellin, and J.-C. Schwartz.
The Histamine H3 Receptor: Gene Organization, Multiple Isoforms, Constitutive Activity and Molecular Pharmacology.
In: Histamine Research in the New Millennium (eds. T. Watanabe, H. Timmerman, and K. Yanai), International Congress Series, Vol. 1224, Elsevier Science B.V., Amsterdam 2001, pp. 9-21.
(ISBN: 0-444-50582-2).

H. Stark, J.-M. Arrang, X. Ligneau, M. Garbarg, C. R. Ganellin, J.-C. Schwartz, and W. Schunack.
The Histamine H3 Receptor and its Ligands.
Prog. Med. Chem. 2001, 38, 279-308;
(eds. F. D. King, A. W. Oxford) Elsevier Science, Amsterdam 2001.
(ISBN: 0-444-50636-5).

M. Krause, H. Stark, and W. Schunack.
Medicinal Chemistry of Histamine H3 Receptor Agonists.
In: The Histamine H3 Receptor: A Target for New Drugs (eds. R. Leurs and H. Timmerman). In: Pharmacochemistry Library (ed. H. Timmerman), Vol. 30, Elsevier Science, Amsterdam 1998, pp. 175-196.
(ISBN: 0-444-82936-9).

R. D. E. Sewell, H. J. Smith, H. Stark, W. Schunack, and P. G. Strange.
Neurotransmitters, Agonists and Antagonists.
In: Smith and Williams` Introduction to the Principles of Drug Design and Action. 4th Edition (ed. H. J. Smith), CRC Press – LLC, Taylor & Francis Group, Boca Raton, Fla USA 2006, pp. 523-556 (Text book).
(ISBN: 978-0-415-28877-4).

R. D. E. Sewell, R. A. Glennon, M. Dukat, H. Stark, W. Schunack, and P. G. Strange.
Neurotransmitters, Agonists and Antagonists.
In: Smith and Williams` Introduction to the Principles of Drug Design and Action. 3rd Edition (ed. H. J. Smith), Harwood Academic Publishers, Amsterdam 1998, pp. 387-433 (Text book).
(ISBN: 0-415-28877-0)

M. Ponchant, S. Demphel, C. Fuseau, C. Coulomb, M. Bottlaender, J.-C. Schwartz, H. Stark, W. Schunack, S. Athmani, R. Ganellin, and C. Crouzel.
Radiosynthesis and Biodistribution of Two Potential Antagonists of Cerebral Histamine H3 Receptors for PET Studies: [18F]FUB 272 and [11C]UCL 1829.
In: XIIth International Symposium on Radiopharmaceutical Chemistry. Uppsala/Sweden 1997 (June 15 – 19, 1997) pp. 605-608.

H. Stark und W. Schunack.
Struktur-Wirkungsbeziehungen und therapeutische Möglichkeiten von Histamin-H3-Agonisten.
In: Entzündungen und verwandte Reaktionen - neue Erkenntnisse, neue Wirkstoffe (ed. R. Hirschelmann), Jena 1993, pp. 113 - 128.

R. Lipp, H. Stark, and W. Schunack.
Pharmacochemistry of H3-Receptors.
In: The Histamine Receptor (eds. J.-C. Schwartz and H. L. Haas) Ser.: Receptor Biochemistry and Methology, vol. 16; Wiley-Liss, New York1992; pp. 57-72.

M. Garbarg, J.-M. Arrang, C. Llorens-Cortes, H. Pollard, A. Rouleau, J.-C. Schwartz, M. D. Trung Tuong, R. Lipp, H. Stark, W. Schunack, and J.-M. Lecomte.
Autoreceptors and Heteroreceptors Evidenced by Histamine H3 Receptor Ligands.
In: Advances In The Biosciences Vol. 82 (Presynaptic Receptors and Neuronal Transporters) (eds. S. Z. Langer, A. M. Galzin, and J. Costentin) Pergamon Press, Oxford 1992; pp. 67-70.

J. Kleine-Tebbe, J. Schramm, M. Bolz, H. Gagné, C. Josties, R. Lipp, A. Friese, H. Stark, V. Zingel, A. Buschauer, W. Schunack, and G. Kunkel.
Influence of Histamine H1, H2 and H3 Agonists and Antagonists on IgE Mediated Histamine Release from Human Basophils.
In: New Trends in Allergy III (eds. J. Ring and B. Przybilla) Springer-Verlag, Berlin 1991; pp. 152-157.

J.-M. Arrang, M. Garbarg, J.-C. Schwartz, R. Lipp, H. Stark, W. Schunack, and J.-M. Lecomte.
The Histamine H3-Receptor: Pharmacology, Roles and Clinical Implications Studied with Agonists.
Agents Actions 1991, 33 (Suppl.), 55-68.

M. Falkenstein und H. Stark.
Hilfe für die wenigen – Noch immer fehlen Orphan Drugs für seltene Erkrankungen.
Deutsche Apotheker Zeitung 2018, in press.

H. Brückmann, S. Zhong und H. Stark.
Blick in die Zukunft – Neue Wirkstoffe gegen atopische Dermatitis im Markt und in der Pipeline.
Deutsche Apotheker Zeitung 2018, 158 (31), 3130-3136 (46-52)

H. Brückmann, S. Zhong und H. Stark.
Juckreiz, Schuppen, Rötung – Pathogenese und leitliniengerechte Therapie der Atopischen Dermatitis.
Deutsche Apotheker Zeitung 2018, 158 (31), 3126-3129 (42-45)

A. Link, S. Wulle, A. Helmstädter, S. Laufer und H. Stark.
Raubjournale – Der Niedergang der wissenschaftlichen Publikationskultur?
Statement der Deutschen Pharmazeutischen Gesellschaft (26.07.2018)

B. Clement, P. Gmeiner, S. Laufer, H. Stark, and D. Steinhilber.
Die Bedeutung des pharmazeutischen Wirkstoffs und die Rolle der Pharmzeutischen/Medizinischen Chemie für einen kompetenzorientierten Lernzielkatalog Pharmazie.
Pharmakon 2018, 6 (3), 228-232.

H. Stark and A. Zivkovic.
HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe.
Acta Facultitatis, Medicae Naissensis (Facta Universitatis, Series Medicine and Biology) 2018, 35 (1), 5-16. doi: 10.2478/afmani-2018-0001.

H. Stark.
Vom Synthesekolben bis zur Schlafkrankheit. – PZ-Highlight.
Pharmazeutische Zeitung 2018, 163 (6), 336-337 (pp.18-19 - 08.02.2018).

T. Dingermann und H. Stark.
Editorial: Fühlen Sie „Ameisen in den Beinen“?
Pharmakon 2018, 6 (1), 1.

S. Hagenow and H. Stark.
From Magic Bullet to Magic Pumpgun: Multi-Targeting Drugs for Neurodegenerative Diseases.
ScienceTrends (October 28, 2017);
https://sciencetrends.com/magic-bullet-magic-pump-gun-multi-targeting-drugs-neurodegenerative-diseases/

A. Frank and H. Stark.
Another Piece of Puzzle in Adjuvant Treatment of Inflammatory Diseases with Natural Compounds.
ScienceTrends (October 20, 2017);
https://sciencetrends.com/another-piece-puzzle-adjuvant-treatment-inflammatory-diseases-natural-compounds/

H. Stark.
Further Developments.
Arch. Pharm. Chem. Life Sci. 2017, 350, e1770010.

S. Hagenow and H. Stark.
Promiscuous Drugs Exemplified by Dopamine Receptor Ligands.
Atlas of Science (Layman´s Summary),
(http://atlasofscience.org/promiscuous-drugs-exemplified-by-dopamine-receptor-ligands/; Dec. 7, 2016).

H. Brückmann, L. Stank und H. Stark.
Morbus Parkinson – Bekannte Arzneistoffe neue entdecken.
Pharmazeutische Zeitung 2016, 161 (43), 3194-3201.

H. Stark.
Meet Our Editorial Board Member.
Curr. Med. Chem. 2016, 23 (33), 3753.

H. Brückmann, L. Stank und H. Stark.
Parkinson-Therapie in Bewegung.
Pharmazeutische Zeitung 2016, 161 (38), 2716-2724.

H. Stark.
Next Steps in Advancing Publication.
Arch. Pharm. Chem. Life Sci. 2015, 348, 1.

H. Stark.
PFT-Belastung muss man ernst nehmen.
Westdeutsche Zeitung, 15. Februar 2014, p. 18 (Gastkommentar).

H. Stark und D. Vogt.
Pharmakotherapie der ADHS.
Pharmazeutische Zeitung 2014, 159 (3), 97

H. Stark
IQWiG vergibt Negativdossier über Lisdexamfetamin.
Pharmakon 2014,4, 49.

T. Dingermann und H. Stark.
Editorial: Zappelphilipp ist nicht ADHS.
Pharmakon 2014, 2, 1.

D. Vogt und H. Stark.
Geheimnisvolle Sphingolipide – Komplexes Netzwerk wichtiger Botenstoffe.
G.I.T.-Labor-Fachzeitschrift 2014, 58(2), 47-49.

H. Stark.
Preface
Histamine H4 receptor: A novel drug target for immunoregulation and inflammation.
(Editor H. Stark, eBook – open access) Versita, London/UK, 2013, pp. 3.
ISBN: 978-83-7656-056-4

H. Stark und J. Stark-Kreul.
Ich höre was, was Du nicht hörst – Tinnitus: Das Pfeifen im Ohr.
Stadtspiegel-Exklusiv Herten/Marl 13. Oktober 2012, p.10.

H. Stark.
Bewertung - PPI in der Selbstmedikation.
Pharmazeutische Zeitung 2012, 157 (3), 180-181.

A. Lill und H. Stark.
Sphingolipide – Fettähnliche Botenstoffe mit großer Wirkung.
PZ - Prisma 2012, 19, 17-27.

D. Vogt und H. Stark.
Fingolimod: Novartis untersucht Todesfall (Meldung).
Pharmazeutische Zeitung 2011, 156 (51), 4704 (30).

H. Stark.
Walter Schunack (1935 – 2011).
Inflamm. Res. 2011, 60 (Suppl. 2), S326.

A.Lill und H. Stark.
Multiple Sklerose – Neuer Therapieansatz mit Fingolimod.
PZ Prisma 2011, 18, 200-202.

K. Sander und H. Stark.
Arzneistoffforschung – Neue Generationen von Antihistaminika.
Pharmazeutische Zeitung 2011, 156 (32), 2750 - 2759.

A.Lill, A. Zivkovic und H. Stark.
Multiple Sklerose – Fortschritt durch perorale Therapien.
Pharmazeutische Zeitung 2011, 156 (24), 2120-2127.

H. Stark.
Koryphäe der Biochemie.
UniReport 2011, 44(3), 4.

H. Stark.
Antihistaminika - Wach durch die Allergiesaison.
Pharmazeutische Zeitung 2011, 156, 1130-1131.

H. Stark.
Tinnitus - Ich höre was, was Du nicht hörst.
Pharmazeutische Zeitung 2010, 155, 4564-4573.

A. Link, M. Schubert-Zsilavecz, H. Stark und M. Stein.
DPhG und Japan – Wissenschaft lebt vom internationalen Austausch.
Pharmazeutische Zeitung 2010, 155 (17), 106-107.
Deutsche Apotheker Zeitung 2010, 150 (17), 1948-1949.
DPhG-Verlautbarung www.dphg.de/read_news/

K. Sander, A. Zivkovic, und H. Stark.
Histamine und ihre Rezeptoren – Internationaler COST-Aktion-Workshop in Frankfurt.
UniCampus – Goethe-Universität 2009, 8, 12+14 (16. Dezember 2009).

K. Sander, A. Zivkovic, und H. Stark.
Internationales Symposium über H4-Rezeptoren.
Deutsche Apotheker Zeitung 2009, 149, 5034-5035.

K. Sander, A. Zivkovic, und H. Stark.
Internationaler COST-Aktion-Workshop.
Pharmazeutische Zeitung 2009, 44, 4177-4178.

H. Stark.
Medicinal Chemistry on Membrane Receptors.
Sonderheft Goethe-Universität – FB14, 2009, 88-90.

K. Sander und H. Stark.
Die Clobutinol-Story.
Pharm. unserer Zeit 2008, 37, 466.

N. Bakthiari und H. Stark.
GDNF erhält catecholaminerge Neurone.
Pharm. unserer Zeit 2008, 37, 445-446.

E. Wenzel und H. Stark.
Cocain-Bindungsstelle am Dopamintransporter geklärt.
Pharm. unserer Zeit 2008, 37, 444.

H. Stark.
Editorial: PSJ and DPhG - Pharmaceutical Societies of Japan and Germany.
Arch. Pharm. Chem. Life Sci. 2008, 341, 521.

J. Black, R. Leurs, H. Stark, and G. Sturman.
Honorary Membership of the European Histamine Research Society (EHRS).
Inflamm. Res. 2008, 57 (Suppl. 1), S03-S04.

H. Stark.
Histamine Receptors.
Biotrend Review (Wangen/Austria) No. 1/11-2007.

H. Stark, M. Amon, and M. Bolte.
1-(3-{4-[(2,4-Dinitroanilino)methyl]phenoxy}propyl)piperidinium chloride.
Acta Cryst. 2007, E63, o4074.

A. Link and H. Stark.
Editorial: Designs that Enrich Lives.
Arch. Pharm. Chem. Life Sci. 2007, 340, 509-510.

U. Holzgrabe, M. Schubert-Zsilavecz, K. Mohr, H. Stark, und T. Dingermann.
„Pillenwarnung“ der AOK-Hessen.
Stellungnahmen der DPhG (www.dphg.de/verlautbarungen/) (1.Dez. 2006),
Deutsche Apotheker Zeitung 2006, 36, 5220 u.a.

J. M. Stein, M. Schubert-Zsilavecz, D. Steinhilber, H. Stark, und O. Werz.
Wie sekundäre Pflanzeninhaltsstoffe uns vor Krankheiten schützen – Von molekularen Wirkmechanismen zu neuen Medikamenten.
Forschung Frankfurt 2006, 4, 32-38.

O. Saur und H. Stark.
Neuroprotektives B2 verstärkt Ablagerung fehlgefalteter Proteine bei C. Huntington und M. Parkinson.
Pharm. unserer Zeit 2006, 35(6), 474-475.

H. Stark.
Editorial: Impact and other Improvements.
Arch. Pharm. Chem. Life Sci. 2006, 339, 345.

H. Stark.
Morbus Parkinson – Bewährte Therapien und neue Perspektiven.
Pharmazeutische Zeitung 2006, 151(21), 1976-1984

H. Stark.
Kaffee gegen M. Parkinson?
[Coffee against Parkinson Disease?]
Pharm. unserer Zeit 2006, 35(3), 188.

H. Stark.
Retinazellen gegen M. Parkinson.
[Retinal Cells against Parkinson Disease].
Pharm. unserer Zeit 2006, 35(3), 189.

H. Stark.
Bildung und Zukunft.
Spektrum, Landesapothekerverband Niedersachsen e.V., 2006, 1/06, 20

T. Kottke und H. Stark.
Komplexe Regulationen bei Dopamin-D2-Rezeptoren.
[Complex Regulation on Dopamine D2 Receptors].
Pharm. unserer Zeit 2006, 36, 9-11.

H. Stark.
Droht eine Influenza-Pandemie?
Deutsche Apotheker Zeitung 2005, 80(44), 5878-5880.

S. Gentsch, T. Dingermann und H. Stark.
Auswahlgespräche für Studienbewerber Pharmazie.
Deutsche Apotheker Zeitung 2005, 72(35), 4707-4709.

H. Stark.
Editorial: Frontiers in GPCR Research.
Arch. Pharm. Chem. Life Sci. 2005, 338, 207.

H. Stark.
Editorial: A New Face for Archiv der Pharmazie.
Arch. Pharm. Chem. Life Sci. 2005, 338, 1.

H. Stark.
Medizinische Chemie zur Beeinflussung von Neurotransmittern.
Medicinal Chemistry on Neurotransmitter Innervation.
Sonderheft zur Bunsentagung 2005, pp. 101-103.

H. Stark.
Editorial: Dedication to H. Schönenberger and Thank to R. Hartmann.
Arch. Pharm. Pharm. Med. Chem. 2004, 337, 207.

A. Kulm, J. Müller, T. Schatton und H. Stark.
Neuropathischer Schmerz – Klassifizierungen und Behandlungsoptionen.
Pharmazeutische Zeitung 2004, 149, 3642-3651.

H. Stark.
Neues zum alten Histamin II. Ionenkanäle in Drosophila.
[News on the Old Histamine. II. Ion Channels in Drosophila.]
Pharm. unserer Zeit 2003, 32, 93.

H. Stark, B. Schlegel, und W. Sippl.
Neues zum alten Histamin I. Ein weiteres Mitglied in der Rezeptorfamilie.
[News on the Old Histamine. I. A Widening of the Receptor Family.]
Pharm. unserer Zeit 2003, 32, 92-93.

H. Stark.
Editorial Preface – Penetration of Blood-Brain Barrier.
Curr. Med. Chem. Centr. Nerv. Syst. Agents, 2002, 2, 174.
(and design of Front Cover).

M. Garbarg, J.-M. Arrang, W. Schunack, R. LIpp, H. Stark, J.-M. Lecomte and J.-C. Schwartz, Nouveaux composés agonistes du récepteur H3 de l'histamine á usage thérapeutique, compositions pharmaceutiques agissant comme agonistes dudit récepteur et procédé de preparation.
FR 2 661 909
WO 91/17 146
US 5,342,960
EP 0 482 183
CA 20 63 550
JP 06/501 241
JP 30 94 384
GR
3024991 T
DE 69 127 045
ES 21 07 464
AT 0156 121
DK 0482 183

 

J.-C. Schwartz, J.-M. Arrang, M. Garbarg, J.-M. .Lecomte, C.R. Ganellin, A. Fkyerat, W. Tertiuk, W. Schunack, R. Lipp, H. Stark, and K. Purand, Antagonistes du récepteur H3 de l'histamine á usage thérapeutique et le procédé de preparation.
FR 26 86 084
WO 93/14 070
US 5,559 113
, US RE37,303
CA 21 05 867
EP 05 97 088
JP6506003
; JP 38292259.
US 5,708 171
DE 69 32 97 27
ES 212 54 270
DK 597 088
AT 197
PT 597088
GR 3035414

 

J.-C. Schwartz, J.-M. Arrang, M. Garbarg, A. Quemener, J.-M. Lecomte, X. Ligneau, W. Schunack, H. Stark, K. Purand, A, Hüls, S. Reidemeister, S. Athmani, C. R. Ganellin, N. Pelloux-Léon, W. Tertiuk, M. C. O. Krause, and B. Sadek,
Nouveaux dérivés de l´imidazole antagonistes et/ou agonistes du récepteur H3 de l´histamine, leur préparation et leurs applications thérapeutiques.
FR 02 732 0).
WO 96/29 315
EP 076 081 1
US 6,248,765
CA
2.190.865
MX 965 687
JP 10501001

 

J.-C. Schwartz, J.-M. Arrang, M. Garbarg, J.-M. Lecomte, X. Ligneau, W. Schunack, H. Stark, C. R. Ganellin, F. Leurquin, and S. Elz.
Non-imidazole Aryloxy (or Arylthio) Alkylamines as Histamine H3-Receptor Antagonists and Their Therapeutic Applications.
EP 0 978 512
 

J.-C. Schwartz, J.-M. Arrang, M. Garbarg, J.-M. Lecomte, X. Ligneau, W. Schunack, H. Stark, C. R. Ganellin, F. Leurquin, and S. Elz.
Non-imidazole Alkylamines as Histamine H3-Receptor Ligands and Their Therapeutic Applications.
EP 0 982 300
WO 00/06254
AU 55 11 999
US 7,169,928
, US 7169928, US 2004 220 225; US 7138413
CA 2.321.881
JP 2002521463

EP 1 100
EP 1 428 820
DK 1100503
AT 276751
DE 69920472T
ES 2226423

PT 1100503T.
DE 69931409
DK 1428820
AT 326446
EP 1428820
ES 2260703
PT 1428820
US 2006247223

 

M. Raga, J. Sallares, M. Guerriero, A. Guglietta, J.-C. Schwartz, J.-M. Lecomte, W. Schunack, J.-M. Arrang, X. Ligneau, H. Stark, and C. R. Ganellin. (Formerly: Ferrer International, S. A.; now: Bioprojet).
Monohydrochloride salt of 1-[3-[3-(4chlorophenyl)propoxy]propyl]-piperidine.
WO 2006084833
EP 1690858, EP 06708050.7, EP 1846384
AR 054734
EP 1846384
CA 2597016
UY29369
KR20070101381
AT 391716
AT 402154
CN 101155793
JP 2007554541, JP 2008530050, JP5072604
US2008221162, US8207197
HRP 20080446
DK 1846384
SI 1846384
PT1846384
MX2007009574
ES2309948
US2012289546   
US8354430
TWI393711
CY1108428
RS50624

 

J. Sallares, I. Petschen, X. Camps, W. Schunack, H. Stark, and M. Capet (Bioprojet (Ferrer International, S. A.)).
Process for preparing 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine.
EP 1910323
WO 2007006708
AR 054530
TWI382975

 

H. Stark, J. M. Leppanen, B. C. Sasse, O. Saur, T. Kottke, and M. P. Hill.
Medicaments (Preparation of 6-amino-4,5,6,7-tetrahydrobenzthiazole derivatives and related analogous as dopamine receptor agonists for treating Parkinson´s disease).
WO 2009 056805
GB 20070021333
EP 2220060
US2011046153, US8389555

 

H. Stark, J. M. Leppanen, B. C. Sasse, O. Saur, T. Kottke, and M. P. Hill.
Medicaments (Preparation of 6-amino-4,5,6,7-tetrahydrobenzthiazole derivatives as dopamine receptor ligands).
WO 2009 056811
GB 20070021332

 

H. Stark, A. Zivkovic, A. Huwiler, and J. Pfeilschifter (Inventors and Applicants).Novel Sphingolipid Heterocyclic Compounds as Modulators of Sphingolipid Signaling and Uses Thereof.

a)    Europäische Patentanmeldung, EP2505589 (A1) (EP Appl. 11160903.8) (April 1, 2011; publ. date Oct. 3, 2012).

b)    Europäische Patentanmeldung, EP2694519 (A1) (EP Appl. 2012 055980) (April 1, 2012), (publ. date: Feb. 12, 2014).

c)    International Patent, PCT WO 2012 131096 A1 (priority date: April 1, 2011: filing date: April 2, 2012;  publication date: October 4, 2012).

d)    United States Patent Application, US201400248 (A1) (April 10, 2014).           

e)    Japanese Patent, JP2014509633 (publ. Date: April 21, 2014).

 

F. Lopez, Muilos, J. L. Marco Contelles, H. Stark, S. Hagenow, and R. R. Ramsey.Nuevos compuestos con capacidad antioxidante que combinan ra inhibicion de las enzimas monoaminooxidasas y colinesterasas y la interaccion con el receptor de histamina 3, su procedimiento de obtencion y composiciones farmaceuticas que los contienen.

 

Spanish Patent Application, No P201731044 (August 23, 2017)

 

 

 

Verantwortlichkeit: